{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Immune Checkpoint Exhaustion", "entry_form": "phenomenon", "gradeable_restatement": "Checkpoint-driven, epigenetically fixed CD8+ T-cell exhaustion is the dominant mechanism by which human solid tumours evade immune control.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Tumour histology, antigen presentation, pretreatment infiltration, lineage compartment, model antigen, disease stage and timing", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Immune Checkpoint Exhaustion", "central_claim": "Checkpoint-driven, epigenetically fixed CD8+ T-cell exhaustion is the dominant mechanism by which human solid tumours evade immune control.", "proposed_mechanism": "Checkpoint-driven, epigenetically fixed CD8+ T-cell exhaustion is the dominant mechanism by which human solid tumours evade immune control.", "claimed_scope": "Checkpoint-driven, epigenetically fixed CD8+ T-cell exhaustion is the dominant mechanism by which human solid tumours evade immune control.", "claimed_level": [ "progression", "maintenance", "relapse" ], "is_conjunctive": true, "conjunctive_note": "Use index scope-matched assessment. SC5 is the gate matching the broad human solid-tumour dominance claim; mechanism and efficacy inside prespecified inflamed, antigen-presenting tumour contexts are reported separately. Terminal-state reversal and progenitor expansion are distinct claims. No responder-defined scope." }, "rubric_routing": { "primary_rubric": "05-immunology-inflammation.md", "secondary_rubrics": [ "02-cancer-biology.md" ], "index_notes_applied": [ "Use index scope-matched assessment. SC5 is the gate matching the broad human solid-tumour dominance claim; mechanism and efficacy inside prespecified inflamed, antigen-presenting tumour contexts are reported separately. Terminal-state reversal and progenitor expansion are distinct claims. No responder-defined scope." ], "rubric_fit_note": "Exact archived v5.3 framework. Any stale index empirical framing is rechecked against primary results." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Tumour-infiltrating T cells enter a reproducible dysfunctional state with inhibitory receptors and lost polyfunctionality.", "subclaim_type": "existence", "scope": "human solid tumours and matched experimental systems", "claimed_scope": "human solid tumours and matched experimental systems", "governing_rubric": "05-immunology-inflammation.md", "key_evidence_anchor": "Cell-resolved longitudinal or clonal functional analysis", "hsef_level": "Β", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Reproducible human cellular states and functional patterns establish association; neither receptor expression nor an atlas alone demonstrates pathway-specific clinical causality." }, { "id": "SC2", "statement": "Exhaustion is a distinct TOX-associated lineage maintained by defined epigenetic programmes.", "subclaim_type": "mechanism", "scope": "prespecified antigen-exposed CD8 T-cell experimental and tumour contexts", "claimed_scope": "prespecified antigen-exposed CD8 T-cell experimental and tumour contexts", "governing_rubric": "05-immunology-inflammation.md", "key_evidence_anchor": "Lineage perturbation, matched epigenetic and functional outcomes", "hsef_level": "Ζ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Defined antigen, chromatin trajectories, TOX or NR4A and other lineage interventions converge on a distinct maintained program in specified experimental contexts; tumour and virus programs are not identical." }, { "id": "SC3", "statement": "The exhaustion programme causally constrains tumour control.", "subclaim_type": "necessity", "scope": "prespecified inflamed, antigen-presenting tumour contexts", "claimed_scope": "prespecified inflamed, antigen-presenting tumour contexts", "governing_rubric": "05-immunology-inflammation.md", "key_evidence_anchor": "Cell-resolved in-vivo perturbations and clinical endpoint checks", "hsef_level": "Ζ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Complementary cell-resolved genetic and targeted pathway interventions change tumour control in prespecified inflamed antigen-presenting models, with human efficacy providing compatible clinical evidence. No claim that terminal exhaustion is the exclusive mediator is made." }, { "id": "SC4", "statement": "PD-1 blockade restores tumour control by reversing terminally exhausted T-cell states.", "subclaim_type": "mechanism", "scope": "terminally exhausted versus progenitor CD8 compartments", "claimed_scope": "terminally exhausted versus progenitor CD8 compartments", "governing_rubric": "05-immunology-inflammation.md", "key_evidence_anchor": "Clonal fate tracing, chromatin state and function after blockade", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Ordinary PD1 benefit often arises from progenitor expansion, persistence or newly detected clones; direct reversal of pre-existing terminal human cells is not established. Distinct rest or cytokine interventions demonstrate partial plasticity rather than validating PD1 reversal." }, { "id": "SC5", "statement": "Exhaustion is the dominant evasion mechanism across human solid tumours.", "subclaim_type": "primacy", "scope": "human solid tumours including antigen-presentation-defective and excluded phenotypes", "claimed_scope": "human solid tumours including antigen-presentation-defective and excluded phenotypes", "governing_rubric": "05-immunology-inflammation.md", "key_evidence_anchor": "Comparative causal effects versus antigen loss, stromal and myeloid escape", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Human clinical efficacy and mechanistic mouse studies do not compare causal dominance across presentation-defective, excluded, myeloid-suppressed and inflamed solid tumours. Negative randomized trials and alternative escape mechanisms block generalization." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "Use index scope-matched assessment. SC5 is the gate matching the broad human solid-tumour dominance claim; mechanism and efficacy inside prespecified inflamed, antigen-presenting tumour contexts are reported separately. Terminal-state reversal and progenitor expansion are distinct claims. No responder-defined scope.", "primary_subclaim_id": "SC5", "aggregation_derivation": "The preregistered scope-matched gate SC5 yields Γ. Defined experimental lineage and tumour-control sensitivities reach Ζ; clinical checkpoint efficacy alone can reach Η in selected indications, but neither establishes terminal-state mediation or cross-solid-tumour dominance. The weakest-link bundle would be Β because of the observational existence subclaim; it is not the registered gate.", "aggregation_alternatives": { "weakest_link_would_return": "Β", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M4", "is_nominal": false, "name": "Progenitor-supported contextual immune control", "core_claim": "Responsive precursors, niches and ongoing differentiation sustain antitumour immunity.", "explains_what_nominal_does_not": "Responsive precursors, niches and ongoing differentiation sustain antitumour immunity.", "strongest_supporting_evidence": [ "Subset ablation and model tracing converge with distinct human clonal trajectories." ], "strongest_contradictory_evidence": [ "Human clone persistence or appearance does not directly label cell fate." ], "hsef_level_for_this_model": "Ζ", "rationale": "Subset ablation and model tracing converge with distinct human clonal trajectories. Human clone persistence or appearance does not directly label cell fate." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Antigen-presentation loss and immunoediting", "core_claim": "Tumour recognition fails through HLA, B2M or IFNgamma pathway defects.", "explains_what_nominal_does_not": "Tumour recognition fails through HLA, B2M or IFNgamma pathway defects.", "strongest_supporting_evidence": [ "Paired acquired-resistance lesions and functional assays support presentation and signaling escape." ], "strongest_contradictory_evidence": [ "Small samples and evolutionary inference do not establish all-tumour prevalence or dominance." ], "hsef_level_for_this_model": "Ε", "rationale": "Paired acquired-resistance lesions and functional assays support presentation and signaling escape. Small samples and evolutionary inference do not establish all-tumour prevalence or dominance." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Stromal exclusion and niche failure", "core_claim": "Fibroblast programs and absent APC niches limit access or support.", "explains_what_nominal_does_not": "Fibroblast programs and absent APC niches limit access or support.", "strongest_supporting_evidence": [ "Cell-resolved CAF depletion and TGFbeta combinations improve experimental control with human spatial concordance." ], "strongest_contradictory_evidence": [ "CAF removal changes composition and function; human depletion efficacy is not established." ], "hsef_level_for_this_model": "Ζ", "rationale": "Cell-resolved CAF depletion and TGFbeta combinations improve experimental control with human spatial concordance. CAF removal changes composition and function; human depletion efficacy is not established." }, { "rank_in_tournament": 4, "model_id": "M5", "is_nominal": false, "name": "Myeloid and regulatory-cell suppression", "core_claim": "TAM, Treg and glucocorticoid circuits restrain effector immunity and priming.", "explains_what_nominal_does_not": "TAM, Treg and glucocorticoid circuits restrain effector immunity and priming.", "strongest_supporting_evidence": [ "Conditional perturbations and complementary functional assays support several circuits." ], "strongest_contradictory_evidence": [ "These compatible mechanisms do not supply one universal clinical ranking." ], "hsef_level_for_this_model": "Ζ", "rationale": "Conditional perturbations and complementary functional assays support several circuits. These compatible mechanisms do not supply one universal clinical ranking." }, { "rank_in_tournament": 5, "model_id": "M1", "is_nominal": true, "name": "Dominant fixed checkpoint exhaustion", "core_claim": "A checkpoint-induced irreversible CD8 program is the central escape mechanism across human solid tumours.", "explains_what_nominal_does_not": "A checkpoint-induced irreversible CD8 program is the central escape mechanism across human solid tumours.", "strongest_supporting_evidence": [ "Clinical checkpoint benefit and stable dysfunctional chromatin make the mechanism plausible." ], "strongest_contradictory_evidence": [ "Program initiation, terminal reversal and cross-tumour dominance cannot be inferred from efficacy or marker abundance." ], "hsef_level_for_this_model": "Γ", "rationale": "Clinical checkpoint benefit and stable dysfunctional chromatin make the mechanism plausible. Program initiation, terminal reversal and cross-tumour dominance cannot be inferred from efficacy or marker abundance." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. Prospective pretreatment stratification and factorial barrier-specific interventions with direct clone and state tracking distinguish a progenitor-supported network from a universal terminal-exhaustion bottleneck.", "study_separating_rank1_from_rank2": "Prospective pretreatment stratification and factorial barrier-specific interventions with direct clone and state tracking distinguish a progenitor-supported network from a universal terminal-exhaustion bottleneck.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "30778252", "title": "Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.", "citation": "Miller BC, Sen DR, Al Abosy R et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature immunology. 2019.", "doi": "10.1038/s41590-019-0312-6", "pmcid": "PMC6673650", "url": "https://pubmed.ncbi.nlm.nih.gov/30778252/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30778252/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID31582823" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30778252", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "what_it_does_not_show": "Subset dependency in models does not establish terminal-state reversal or pan-tumour dominance; linked erratum details unexamined.", "confounders_present": [ "Subset dependency in models does not establish terminal-state reversal or pan-tumour dominance; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 2, "pmid": "29942094", "title": "Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.", "citation": "Guo X, Zhang Y, Zheng L et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nature medicine. 2018.", "doi": "10.1038/s41591-018-0045-3", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29942094/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29942094/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID30093729" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29942094", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Single-cell NSCLC profiling resolves heterogeneous immune states and suppressive populations.", "what_it_does_not_show": "Atlas association does not rank causal bottlenecks; linked erratum details unexamined.", "confounders_present": [ "Atlas association does not rank causal bottlenecks; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 3, "pmid": "33795428", "title": "Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.", "citation": "Weber EW, Parker KR, Sotillo E et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science (New York, N.Y.). 2021.", "doi": "10.1126/science.aba1786", "pmcid": "PMC8049103", "url": "https://pubmed.ncbi.nlm.nih.gov/33795428/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33795428/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33795428", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "what_it_does_not_show": "CAR rest is a different intervention from PD1 blockade and does not prove terminal human tumour T-cell reversal.", "confounders_present": [ "CAR rest is a different intervention from PD1 blockade and does not prove terminal human tumour T-cell reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 4, "pmid": "35978192", "title": "MYB orchestrates T cell exhaustion and response to checkpoint inhibition.", "citation": "Tsui C, Kretschmer L, Rapelius S et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022.", "doi": "10.1038/s41586-022-05105-1", "pmcid": "PMC9452299", "url": "https://pubmed.ncbi.nlm.nih.gov/35978192/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35978192/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35978192", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "what_it_does_not_show": "Chronic-virus lineage dependency is a mechanism comparator rather than human solid-tumour causality.", "confounders_present": [ "Chronic-virus lineage dependency is a mechanism comparator rather than human solid-tumour causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 5, "pmid": "33398183", "title": "Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion.", "citation": "Scharping NE, Rivadeneira DB, Menk AV et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nature immunology. 2021.", "doi": "10.1038/s41590-020-00834-9", "pmcid": "PMC7971090", "url": "https://pubmed.ncbi.nlm.nih.gov/33398183/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33398183/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33398183", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "what_it_does_not_show": "Metabolic and environmental effects are not isolated proof that checkpoints initiate the epigenetic program.", "confounders_present": [ "Metabolic and environmental effects are not isolated proof that checkpoints initiate the epigenetic program." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 6, "pmid": "37001526", "title": "Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.", "citation": "Pai JA, Hellmann MD, Sauter JL et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer cell. 2023.", "doi": "10.1016/j.ccell.2023.03.009", "pmcid": "PMC10563767", "url": "https://pubmed.ncbi.nlm.nih.gov/37001526/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37001526/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37001526", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Multiregion human lung-cancer profiling links persistent progenitor clones in lymph nodes with tumour descendants.", "what_it_does_not_show": "Clonal and computational relationships are not direct in-vivo human fate labeling or universal causal mediation.", "confounders_present": [ "Clonal and computational relationships are not direct in-vivo human fate labeling or universal causal mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 7, "pmid": "31207604", "title": "TOX is a critical regulator of tumour-specific T cell differentiation.", "citation": "Scott AC, Dündar F, Zumbo P et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019.", "doi": "10.1038/s41586-019-1324-y", "pmcid": "PMC7698992", "url": "https://pubmed.ncbi.nlm.nih.gov/31207604/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31207604/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "AST liver-antigen platform; TOX perturbation and human samples", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph6, 0:METHODS:paragraph11, 0:METHODS:paragraph13, 0:METHODS:paragraph14, 0:METHODS:paragraph17, 0:METHODS:paragraph18, 0:METHODS:paragraph23, 0:METHODS:paragraph31, 0:METHODS:paragraph37, 0:METHODS:paragraph38, 3:Main text (unsectioned body paragraphs):paragraph0, 3:Main text (unsectioned body paragraphs):paragraph1, 3:Main text (unsectioned body paragraphs):paragraph2, 3:Main text (unsectioned body paragraphs):paragraph3, 3:Main text (unsectioned body paragraphs):paragraph4, 3:Main text (unsectioned body paragraphs):paragraph5, 3:Main text (unsectioned body paragraphs):paragraph6, 3:Main text (unsectioned body paragraphs):paragraph7, 3:Main text (unsectioned body paragraphs):paragraph8, 3:Main text (unsectioned body paragraphs):paragraph9, 3:Main text (unsectioned body paragraphs):paragraph10, 3:Main text (unsectioned body paragraphs):paragraph11. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "what_it_does_not_show": "TOX marker loss is not functional rescue. Experiments were not randomized or blinded and had no sample-size predetermination; human samples are observational, including infiltrate-selected breast cancers.", "confounders_present": [ "TOX marker loss is not functional rescue. Experiments were not randomized or blinded and had no sample-size predetermination; human samples are observational, including infiltrate-selected breast cancers." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 8, "pmid": "36208623", "title": "The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes.", "citation": "Huang Q, Wu X, Wang Z et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022.", "doi": "10.1016/j.cell.2022.09.020", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36208623/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36208623/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID36208623", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "what_it_does_not_show": "A nodal source mechanism does not establish reversal of terminal intratumoral cells or clinical dominance.", "confounders_present": [ "A nodal source mechanism does not establish reversal of terminal intratumoral cells or clinical dominance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 9, "pmid": "35623342", "title": "Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.", "citation": "Kersten K, Hu KH, Combes AJ et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer cell. 2022.", "doi": "10.1016/j.ccell.2022.05.004", "pmcid": "PMC9197962", "url": "https://pubmed.ncbi.nlm.nih.gov/35623342/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35623342/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35623342", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "what_it_does_not_show": "Changing macrophages affects additional functions and does not establish a single universal exhaustion bottleneck.", "confounders_present": [ "Changing macrophages affects additional functions and does not establish a single universal exhaustion bottleneck." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 10, "pmid": "33636129", "title": "In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer.", "citation": "Chen Z, Arai E, Khan O et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021.", "doi": "10.1016/j.cell.2021.02.019", "pmcid": "PMC8054351", "url": "https://pubmed.ncbi.nlm.nih.gov/33636129/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33636129/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33636129", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "what_it_does_not_show": "Different disease systems and transcription-factor perturbation do not isolate ordinary PD1-mediated terminal reversal.", "confounders_present": [ "Different disease systems and transcription-factor perturbation do not isolate ordinary PD1-mediated terminal reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 11, "pmid": "39121848", "title": "LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity.", "citation": "Andrews LP, Butler SC, Cui J et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024.", "doi": "10.1016/j.cell.2024.07.016", "pmcid": "PMC11323044", "url": "https://pubmed.ncbi.nlm.nih.gov/39121848/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39121848/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39121848", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "what_it_does_not_show": "Dual conditional pathway effects do not prove that all human resistant tumours are limited by fixed CD8 exhaustion.", "confounders_present": [ "Dual conditional pathway effects do not prove that all human resistant tumours are limited by fixed CD8 exhaustion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 12, "pmid": "33891860", "title": "A unified atlas of CD8 T cell dysfunctional states in cancer and infection.", "citation": "Pritykin Y, van der Veeken J, Pine AR et al. A unified atlas of CD8 T cell dysfunctional states in cancer and infection. Molecular cell. 2021.", "doi": "10.1016/j.molcel.2021.03.045", "pmcid": "PMC8454502", "url": "https://pubmed.ncbi.nlm.nih.gov/33891860/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33891860/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Integrated public exhaustion datasets plus new viral experiments", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Integrated chromatin and transcriptional datasets plus viral experiments resolve exhaustion-associated trajectories.", "what_it_does_not_show": "Reused atlas datasets share failure modes and viral mechanisms need separate tumour validation.", "confounders_present": [ "Reused atlas datasets share failure modes and viral mechanisms need separate tumour validation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 13, "pmid": "31207605", "title": "TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.", "citation": "Alfei F, Kanev K, Hofmann M et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019.", "doi": "10.1038/s41586-019-1326-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31207605/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31207605/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31207605", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "what_it_does_not_show": "The outcome argues against a simple uniformly harmful lineage; it is not a human tumour treatment trial.", "confounders_present": [ "The outcome argues against a simple uniformly harmful lineage; it is not a human tumour treatment trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 14, "pmid": "38091951", "title": "Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure.", "citation": "Beltra JC, Abdel-Hakeem MS, Manne S et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. Immunity. 2023.", "doi": "10.1016/j.immuni.2023.11.005", "pmcid": "PMC10752292", "url": "https://pubmed.ncbi.nlm.nih.gov/38091951/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38091951/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID38091951", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "what_it_does_not_show": "Targeted cytokine rewiring is not equivalent to PD1 blockade or complete durable terminal-state reversal in patients.", "confounders_present": [ "Targeted cytokine rewiring is not equivalent to PD1 blockade or complete durable terminal-state reversal in patients." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 15, "pmid": "37537361", "title": "Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division.", "citation": "Rudloff MW, Zumbo P, Favret NR et al. Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division. Nature immunology. 2023.", "doi": "10.1038/s41590-023-01578-y", "pmcid": "PMC10878719", "url": "https://pubmed.ncbi.nlm.nih.gov/37537361/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37537361/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37537361", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "what_it_does_not_show": "Rapid onset in a defined model does not identify a checkpoint as the initiating cause across solid tumours.", "confounders_present": [ "Rapid onset in a defined model does not identify a checkpoint as the initiating cause across solid tumours." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 16, "pmid": "39121849", "title": "Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity.", "citation": "Cillo AR, Cardello C, Shan F et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024.", "doi": "10.1016/j.cell.2024.06.036", "pmcid": "PMC11346583", "url": "https://pubmed.ncbi.nlm.nih.gov/39121849/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39121849/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39121849", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "what_it_does_not_show": "Molecular response is compatible with continuing exhaustion programs; it is not a terminal-fate-mediated survival trial.", "confounders_present": [ "Molecular response is compatible with continuing exhaustion programs; it is not a terminal-fate-mediated survival trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 17, "pmid": "32937153", "title": "Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment.", "citation": "Acharya N, Madi A, Zhang H et al. Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity. 2020.", "doi": "10.1016/j.immuni.2020.08.005", "pmcid": "PMC7682805", "url": "https://pubmed.ncbi.nlm.nih.gov/32937153/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32937153/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32937153", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "what_it_does_not_show": "Parallel environmental suppression and checkpoint effects need mediation separation.", "confounders_present": [ "Parallel environmental suppression and checkpoint effects need mediation separation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 18, "pmid": "31152140", "title": "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion.", "citation": "Seo H, Chen J, González-Avalos E et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "doi": "10.1073/pnas.1905675116", "pmcid": "PMC6589758", "url": "https://pubmed.ncbi.nlm.nih.gov/31152140/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31152140/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID31527257" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related hCD19 CAR TOX/TOX2 platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "what_it_does_not_show": "Shared CAR platform with NR4A experiments limits independence; linked erratum details unexamined.", "confounders_present": [ "Shared CAR platform with NR4A experiments limits independence; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 19, "pmid": "34879221", "title": "Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity.", "citation": "Hanna BS, Llaó-Cid L, Iskar M et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity. 2021.", "doi": "10.1016/j.immuni.2021.11.004", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34879221/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34879221/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34879221", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "what_it_does_not_show": "CLL is not a solid tumour and protective IL10 effects are context dependent; no cross-solid-tumour clinical proof.", "confounders_present": [ "CLL is not a solid tumour and protective IL10 effects are context dependent; no cross-solid-tumour clinical proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 20, "pmid": "31359002", "title": "Clonal replacement of tumor-specific T cells following PD-1 blockade.", "citation": "Yost KE, Satpathy AT, Wells DK et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature medicine. 2019.", "doi": "10.1038/s41591-019-0522-3", "pmcid": "PMC6689255", "url": "https://pubmed.ncbi.nlm.nih.gov/31359002/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31359002/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31359002", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Main. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Original Results profile 11 paired BCC patients and four SCC patients; bulk TCR sequencing in eight BCC patients and serial same-site biopsies address sampling. Expanded exhausted clones often are newly detected and retain exhausted phenotypes.", "what_it_does_not_show": "The source of new clones was not identified and rare tumour-resident cells remain possible. Blood detection supports but does not prove recruitment; this is not terminal-state lineage perturbation in humans.", "confounders_present": [ "The source of new clones was not identified and rare tumour-resident cells remain possible. Blood detection supports but does not prove recruitment; this is not terminal-state lineage perturbation in humans." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 21, "pmid": "34031618", "title": "Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.", "citation": "Guo Y, Xie YQ, Gao M et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nature immunology. 2021.", "doi": "10.1038/s41590-021-00940-2", "pmcid": "PMC7610876", "url": "https://pubmed.ncbi.nlm.nih.gov/34031618/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34031618/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34031618", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "what_it_does_not_show": "A distinct intervention shows some plasticity but does not imply PD1 blockade normally reverses all terminal states.", "confounders_present": [ "A distinct intervention shows some plasticity but does not imply PD1 blockade normally reverses all terminal states." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 22, "pmid": "27501248", "title": "Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.", "citation": "Im SJ, Hashimoto M, Gerner MY et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016.", "doi": "10.1038/nature19330", "pmcid": "PMC5297183", "url": "https://pubmed.ncbi.nlm.nih.gov/27501248/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27501248/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27501248", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "what_it_does_not_show": "Chronic viral infection is a mechanism comparator rather than clinical solid-tumour efficacy or human fate proof.", "confounders_present": [ "Chronic viral infection is a mechanism comparator rather than clinical solid-tumour efficacy or human fate proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 23, "pmid": "33007259", "title": "The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.", "citation": "Dammeijer F, van Gulijk M, Mulder EE et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer cell. 2020.", "doi": "10.1016/j.ccell.2020.09.001", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33007259/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33007259/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33007259", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "what_it_does_not_show": "Human nodal association does not establish clinical source necessity or pan-cancer mechanism dominance.", "confounders_present": [ "Human nodal association does not establish clinical source necessity or pan-cancer mechanism dominance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 24, "pmid": "34715028", "title": "Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.", "citation": "Au L, Hatipoglu E, Robert de Massy M et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer cell. 2021.", "doi": "10.1016/j.ccell.2021.10.001", "pmcid": "PMC8599450", "url": "https://pubmed.ncbi.nlm.nih.gov/34715028/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34715028/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34715028", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Longitudinal multiregion renal-cancer samples associate maintained expanded T-cell clones with nivolumab response.", "what_it_does_not_show": "Maintenance correlations constrain a universal replacement account but do not prove causally reversed terminal cells.", "confounders_present": [ "Maintenance correlations constrain a universal replacement account but do not prove causally reversed terminal cells." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 25, "pmid": "41299179", "title": "Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells.", "citation": "Hor JL, Schrom EC, Wong-Rolle A et al. Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells. Nature. 2026.", "doi": "10.1038/s41586-025-09440-x", "pmcid": "PMC12727512", "url": "https://pubmed.ncbi.nlm.nih.gov/41299179/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41299179/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID41299179", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "what_it_does_not_show": "The protective axis is context dependent and does not negate clinical benefits or prove human cross-tumour dominance.", "confounders_present": [ "The protective axis is context dependent and does not negate clinical benefits or prove human cross-tumour dominance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 26, "pmid": "39214097", "title": "Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.", "citation": "Wang K, Coutifaris P, Brocks D et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer cell. 2024.", "doi": "10.1016/j.ccell.2024.08.007", "pmcid": "PMC11387127", "url": "https://pubmed.ncbi.nlm.nih.gov/39214097/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39214097/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39214097", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Serial melanoma profiling identifies distinct waves associated with CTLA4 and PD1 treatment and progenitor or effector responses.", "what_it_does_not_show": "Temporal molecular waves do not uniquely establish reversal of pre-existing terminal cells or mediation of survival.", "confounders_present": [ "Temporal molecular waves do not uniquely establish reversal of pre-existing terminal cells or mediation of survival." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 27, "pmid": "35121991", "title": "Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.", "citation": "Liu B, Hu X, Feng K et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature cancer. 2022.", "doi": "10.1038/s43018-021-00292-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35121991/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35121991/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35121991", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Human lung-cancer paired samples support revival of pre-existing and new clones rather than a single universal clonal route.", "what_it_does_not_show": "Clonal sampling and state inference do not directly trace terminal human T-cell reversal.", "confounders_present": [ "Clonal sampling and state inference do not directly trace terminal human T-cell reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 28, "pmid": "37968405", "title": "Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer.", "citation": "Zhou P, Shi H, Huang H et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature. 2023.", "doi": "10.1038/s41586-023-06733-x", "pmcid": "PMC10700132", "url": "https://pubmed.ncbi.nlm.nih.gov/37968405/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37968405/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37968405", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "what_it_does_not_show": "Gene-specific cell rewiring is distinct from routine checkpoint treatment and may alter several lineage compartments.", "confounders_present": [ "Gene-specific cell rewiring is distinct from routine checkpoint treatment and may alter several lineage compartments." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 29, "pmid": "41005293", "title": "Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4.", "citation": "Alicea Pauneto CDM, Riesenberg BP, Gandy EJ et al. Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 2025.", "doi": "10.1016/j.immuni.2025.09.003", "pmcid": "PMC12666857", "url": "https://pubmed.ncbi.nlm.nih.gov/41005293/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41005293/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID41005293", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "what_it_does_not_show": "Stress pathways provide an alternative input and do not establish exhaustion dominance in patients.", "confounders_present": [ "Stress pathways provide an alternative input and do not establish exhaustion dominance in patients." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 30, "pmid": "39322665", "title": "The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer.", "citation": "Feng B, Bai Z, Zhou X et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024.", "doi": "10.1038/s41586-024-07962-4", "pmcid": "PMC11485240", "url": "https://pubmed.ncbi.nlm.nih.gov/39322665/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39322665/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39322665", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "what_it_does_not_show": "Functional plasticity with another cytokine treatment does not establish ordinary PD1-mediated complete lineage reversal.", "confounders_present": [ "Functional plasticity with another cytokine treatment does not establish ordinary PD1-mediated complete lineage reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 31, "pmid": "36543958", "title": "Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.", "citation": "Vignali PDA, DePeaux K, Watson MJ et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nature immunology. 2023.", "doi": "10.1038/s41590-022-01379-9", "pmcid": "PMC10402660", "url": "https://pubmed.ncbi.nlm.nih.gov/36543958/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36543958/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID36543958", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "what_it_does_not_show": "A suppressor mechanism in specified models does not determine prevalence or dominance across human solid cancers.", "confounders_present": [ "A suppressor mechanism in specified models does not determine prevalence or dominance across human solid cancers." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 32, "pmid": "34836966", "title": "Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.", "citation": "Lee AH, Sun L, Mochizuki AY et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature communications. 2021.", "doi": "10.1038/s41467-021-26940-2", "pmcid": "PMC8626557", "url": "https://pubmed.ncbi.nlm.nih.gov/34836966/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34836966/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34836966", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Neoadjuvant glioblastoma immune profiling shows T-cell and progenitor engagement alongside persistent myeloid barriers.", "what_it_does_not_show": "Target engagement does not guarantee clinical efficacy or removal of non-T-cell resistance.", "confounders_present": [ "Target engagement does not guarantee clinical efficacy or removal of non-T-cell resistance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 33, "pmid": "34102137", "title": "First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.", "citation": "Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England). 2021.", "doi": "10.1016/S0140-6736(21)00797-2", "pmcid": "PMC8436782", "url": "https://pubmed.ncbi.nlm.nih.gov/34102137/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34102137/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34102137", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "what_it_does_not_show": "Combination efficacy does not isolate CD8 exhaustion mediation or imply identical benefits in every biomarker context.", "confounders_present": [ "Combination efficacy does not isolate CD8 exhaustion mediation or imply identical benefits in every biomarker context." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 34, "pmid": "39282897", "title": "Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.", "citation": "Wolchok JD, Chiarion-Sileni V, Rutkowski P et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2407417", "pmcid": "PMC12080919", "url": "https://pubmed.ncbi.nlm.nih.gov/39282897/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39282897/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "CheckMate067 NCT01844505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "what_it_does_not_show": "This is follow-up of the same randomized cohort as the initial report, not an independent replication or terminal-state fate assay.", "confounders_present": [ "This is follow-up of the same randomized cohort as the initial report, not an independent replication or terminal-state fate assay." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Reports use the same clinical cohort; separate report examination is not independent participant replication." ] }, { "n": 35, "pmid": "35403841", "title": "Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.", "citation": "Forde PM, Spicer J, Lu S et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New England journal of medicine. 2022.", "doi": "10.1056/NEJMoa2202170", "pmcid": "PMC9844511", "url": "https://pubmed.ncbi.nlm.nih.gov/35403841/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35403841/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35403841", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "what_it_does_not_show": "The interim OS result in this report did not cross its prespecified threshold; chemotherapy combination does not isolate terminal exhaustion reversal.", "confounders_present": [ "The interim OS result in this report did not cross its prespecified threshold; chemotherapy combination does not isolate terminal exhaustion reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 36, "pmid": "26027431", "title": "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.", "citation": "Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015.", "doi": "10.1056/NEJMoa1504030", "pmcid": "PMC5698905", "url": "https://pubmed.ncbi.nlm.nih.gov/26027431/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26027431/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID31442371" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "CheckMate067 NCT01844505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "what_it_does_not_show": "PFS and the subsequent ten-year follow-up share one cohort; neither directly proves terminal CD8 epigenetic reversal. Linked erratum details unexamined.", "confounders_present": [ "PFS and the subsequent ten-year follow-up share one cohort; neither directly proves terminal CD8 epigenetic reversal. Linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Reports use the same clinical cohort; separate report examination is not independent participant replication." ] }, { "n": 37, "pmid": "20525992", "title": "Improved survival with ipilimumab in patients with metastatic melanoma.", "citation": "Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010.", "doi": "10.1056/NEJMoa1003466", "pmcid": "PMC3549297", "url": "https://pubmed.ncbi.nlm.nih.gov/20525992/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20525992/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID20525992", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "what_it_does_not_show": "CTLA4 acts in broader immune compartments and the trial does not identify terminal CD8 exhaustion as the dominant mediator; linked erratum details unexamined.", "confounders_present": [ "CTLA4 acts in broader immune compartments and the trial does not identify terminal CD8 exhaustion as the dominant mediator; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 38, "pmid": "29562145", "title": "Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.", "citation": "Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018.", "doi": "10.1056/NEJMoa1712126", "pmcid": "PMC5972549", "url": "https://pubmed.ncbi.nlm.nih.gov/29562145/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29562145/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29562145", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "what_it_does_not_show": "PFS did not meet the prespecified significance threshold and favorable-risk or mechanistic generalization is separate.", "confounders_present": [ "PFS did not meet the prespecified significance threshold and favorable-risk or mechanistic generalization is separate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 39, "pmid": "25891173", "title": "Pembrolizumab versus Ipilimumab in Advanced Melanoma.", "citation": "Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015.", "doi": "10.1056/NEJMoa1503093", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25891173/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25891173/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID25891173", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "what_it_does_not_show": "A comparative clinical endpoint does not identify which CD8 lineage mediated benefit.", "confounders_present": [ "A comparative clinical endpoint does not identify which CD8 lineage mediated benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 40, "pmid": "26412456", "title": "Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.", "citation": "Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015.", "doi": "10.1056/NEJMoa1507643", "pmcid": "PMC5705936", "url": "https://pubmed.ncbi.nlm.nih.gov/26412456/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26412456/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID26412456", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "what_it_does_not_show": "Median PFS was not uniformly favorable and PD-L1-dependent heterogeneity does not establish cross-tumour dominance.", "confounders_present": [ "Median PFS was not uniformly favorable and PD-L1-dependent heterogeneity does not establish cross-tumour dominance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 41, "pmid": "26028407", "title": "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.", "citation": "Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015.", "doi": "10.1056/NEJMoa1504627", "pmcid": "PMC4681400", "url": "https://pubmed.ncbi.nlm.nih.gov/26028407/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26028407/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID26028407", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "what_it_does_not_show": "Clinical efficacy is not an assay of exhaustion causality or terminal-state reversal.", "confounders_present": [ "Clinical efficacy is not an assay of exhaustion causality or terminal-state reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 42, "pmid": "36171287", "title": "LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.", "citation": "Krishnamurty AT, Shyer JA, Thai M et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022.", "doi": "10.1038/s41586-022-05272-1", "pmcid": "PMC9630141", "url": "https://pubmed.ncbi.nlm.nih.gov/36171287/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36171287/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related LRRC15 fibroblast lineage, distinct experimental depletion", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 4:LRRC15+ CAF depletion slows tumour growth, 6:LRRC15+ CAFs impede CD8+ T cell function, 7:LRRC15+ CAF ablation boosts ICB responses, 8:Discussion. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "what_it_does_not_show": "Ablation changes total fibroblast abundance and immune state, so its full mechanism is not a single physical barrier; progression-to-size or ulceration survival is not all-cause human survival.", "confounders_present": [ "Ablation changes total fibroblast abundance and immune state, so its full mechanism is not a single physical barrier; progression-to-size or ulceration survival is not all-cause human survival." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 43, "pmid": "32497499", "title": "Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.", "citation": "Oh DY, Kwek SS, Raju SS et al. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020.", "doi": "10.1016/j.cell.2020.05.017", "pmcid": "PMC7321885", "url": "https://pubmed.ncbi.nlm.nih.gov/32497499/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32497499/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32497499", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "what_it_does_not_show": "Ex-vivo killing and response prediction do not establish in-vivo clinical necessity; CD8 exhaustion is not the only candidate compartment.", "confounders_present": [ "Ex-vivo killing and response prediction do not establish in-vivo clinical necessity; CD8 exhaustion is not the only candidate compartment." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 44, "pmid": "31028147", "title": "PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.", "citation": "Kamada T, Togashi Y, Tay C et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "doi": "10.1073/pnas.1822001116", "pmcid": "PMC6525547", "url": "https://pubmed.ncbi.nlm.nih.gov/31028147/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31028147/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31028147", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "what_it_does_not_show": "Human observational hyperprogression is not randomized proof that checkpoint treatment causes accelerated disease.", "confounders_present": [ "Human observational hyperprogression is not randomized proof that checkpoint treatment causes accelerated disease." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 45, "pmid": "33644766", "title": "CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.", "citation": "Solomon I, Amann M, Goubier A et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nature cancer. 2020.", "doi": "10.1038/s43018-020-00133-0", "pmcid": "PMC7116816", "url": "https://pubmed.ncbi.nlm.nih.gov/33644766/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33644766/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33644766", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "what_it_does_not_show": "Cross-system preclinical function is not established human solid-tumour efficacy or a universal CD8-exhaustion bottleneck.", "confounders_present": [ "Cross-system preclinical function is not established human solid-tumour efficacy or a universal CD8-exhaustion bottleneck." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 46, "pmid": "37392735", "title": "CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity.", "citation": "Moreno Ayala MA, Campbell TF, Zhang C et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. Immunity. 2023.", "doi": "10.1016/j.immuni.2023.06.003", "pmcid": "PMC10752240", "url": "https://pubmed.ncbi.nlm.nih.gov/37392735/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37392735/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37392735", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "what_it_does_not_show": "Changing upstream priming provides another constraint and does not establish exhausted CD8 states as autonomous initiators.", "confounders_present": [ "Changing upstream priming provides another constraint and does not establish exhausted CD8 states as autonomous initiators." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 47, "pmid": "31699795", "title": "Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.", "citation": "Dominguez CX, Müller S, Keerthivasan S et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer discovery. 2020.", "doi": "10.1158/2159-8290.CD-19-0644", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31699795/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31699795/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Human LRRC15 fibroblast program", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Pancreatic and multicancer profiling associates LRRC15 fibroblast programs with checkpoint nonresponse.", "what_it_does_not_show": "Clinical correlations are not causal depletion results; this shares a fibroblast biological program with later intervention work.", "confounders_present": [ "Clinical correlations are not causal depletion results; this shares a fibroblast biological program with later intervention work." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 48, "pmid": "27828943", "title": "Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.", "citation": "De Henau O, Rausch M, Winkler D et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016.", "doi": "10.1038/nature20554", "pmcid": "PMC5634331", "url": "https://pubmed.ncbi.nlm.nih.gov/27828943/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27828943/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27828943", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "what_it_does_not_show": "The intervention is not fully cell-specific and preclinical benefit is not human clinical efficacy.", "confounders_present": [ "The intervention is not fully cell-specific and preclinical benefit is not human clinical efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 49, "pmid": "42361199", "title": "Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.", "citation": "Schmiechen ZC, Cruz-Hinojoza E, Hilk AL et al. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology. 2026.", "doi": "10.1126/sciimmunol.adz4302", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42361199/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42361199/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID42361199", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "what_it_does_not_show": "Experimental loss and engineered rescue do not determine frequency or dominance in unselected human pancreatic cancer.", "confounders_present": [ "Experimental loss and engineered rescue do not determine frequency or dominance in unselected human pancreatic cancer." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 50, "pmid": "27789795", "title": "Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.", "citation": "Pauken KE, Sammons MA, Odorizzi PM et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science (New York, N.Y.). 2016.", "doi": "10.1126/science.aaf2807", "pmcid": "PMC5484795", "url": "https://pubmed.ncbi.nlm.nih.gov/27789795/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27789795/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27789795", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "what_it_does_not_show": "Chronic-virus stability is not absolute irreversibility under every intervention or proof of terminal human tumour fate.", "confounders_present": [ "Chronic-virus stability is not absolute irreversibility under every intervention or proof of terminal human tumour fate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 51, "pmid": "28514453", "title": "Chromatin states define tumour-specific T cell dysfunction and reprogramming.", "citation": "Philip M, Fairchild L, Sun L et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017.", "doi": "10.1038/nature22367", "pmcid": "PMC5693219", "url": "https://pubmed.ncbi.nlm.nih.gov/28514453/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28514453/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "AST liver-antigen platform plus B16-OVA and human chromatin", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:CD8 T cell chromatin changes during infection, 2:Chromatin state dynamics of TST dysfunction, 3:Chromatin states are associated with reprogrammability, 4:Surface proteins associated with chromatin states, 5:Memory T cells enter state 2 dysfunction in tumors, 6:Chromatin accessibility in human TIL, 7:Discussion. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "what_it_does_not_show": "The human marker and chromatin comparison does not directly test patient T-cell reversibility; fixed means resistant to the tested conditions, not forever irreprogrammable.", "confounders_present": [ "The human marker and chromatin comparison does not directly test patient T-cell reversibility; fixed means resistant to the tested conditions, not forever irreprogrammable." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 52, "pmid": "31827286", "title": "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.", "citation": "Jansen CS, Prokhnevska N, Master VA et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019.", "doi": "10.1038/s41586-019-1836-5", "pmcid": "PMC7108171", "url": "https://pubmed.ncbi.nlm.nih.gov/31827286/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31827286/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31827286", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC5" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Human tumour stem-like T cells occupy APC-rich niches and correlate with infiltration and nonprogressive disease.", "what_it_does_not_show": "Spatial association does not prove that niche absence causes clinical escape or that terminal exhaustion dominates it.", "confounders_present": [ "Spatial association does not prove that niche absence causes clinical escape or that terminal exhaustion dominates it." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 53, "pmid": "25428505", "title": "PD-1 blockade induces responses by inhibiting adaptive immune resistance.", "citation": "Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014.", "doi": "10.1038/nature13954", "pmcid": "PMC4246418", "url": "https://pubmed.ncbi.nlm.nih.gov/25428505/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25428505/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID25428505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Serial melanoma biopsies associate pre-existing margin CD8 cells and PD1 or PDL1 proximity with pembrolizumab response, with independent predictive validation.", "what_it_does_not_show": "Predictive association and proliferation are not a necessity perturbation or proof of terminal-state mediation.", "confounders_present": [ "Predictive association and proliferation are not a necessity perturbation or proof of terminal-state mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 54, "pmid": "30388456", "title": "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.", "citation": "Sade-Feldman M, Yizhak K, Bjorgaard SL et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018.", "doi": "10.1016/j.cell.2018.10.038", "pmcid": "PMC6641984", "url": "https://pubmed.ncbi.nlm.nih.gov/30388456/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30388456/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID30633907" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30388456", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Melanoma single-cell profiling identifies TCF7-associated states predicting checkpoint outcome and complementary experimental targets.", "what_it_does_not_show": "Predictive human states do not establish fate reversal; linked erratum details unexamined.", "confounders_present": [ "Predictive human states do not establish fate reversal; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 55, "pmid": "27433843", "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.", "citation": "Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England journal of medicine. 2016.", "doi": "10.1056/NEJMoa1604958", "pmcid": "PMC5007206", "url": "https://pubmed.ncbi.nlm.nih.gov/27433843/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27433843/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27433843", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "what_it_does_not_show": "Four patients do not estimate population prevalence or prove every escape event independently; acquired resistance is a distinct stage.", "confounders_present": [ "Four patients do not estimate population prevalence or prove every escape event independently; acquired resistance is a distinct stage." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 56, "pmid": "27903500", "title": "Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.", "citation": "Shin DS, Zaretsky JM, Escuin-Ordinas H et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer discovery. 2017.", "doi": "10.1158/2159-8290.CD-16-1223", "pmcid": "PMC5296316", "url": "https://pubmed.ncbi.nlm.nih.gov/27903500/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27903500/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27903500", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "what_it_does_not_show": "Small selected samples and in-vitro mechanism do not establish universal primary resistance or ranking versus exhaustion.", "confounders_present": [ "Small selected samples and in-vitro mechanism do not establish universal primary resistance or ranking versus exhaustion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 57, "pmid": "29107330", "title": "Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.", "citation": "McGranahan N, Rosenthal R, Hiley CT et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017.", "doi": "10.1016/j.cell.2017.10.001", "pmcid": "PMC5720478", "url": "https://pubmed.ncbi.nlm.nih.gov/29107330/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29107330/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29107330", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Allele-specific HLA loss and tumour phylogenetic patterns support immune selection and presentation escape in NSCLC.", "what_it_does_not_show": "Computational evolutionary evidence does not directly restore HLA or quantify causal superiority over exhaustion in patients.", "confounders_present": [ "Computational evolutionary evidence does not directly restore HLA or quantify causal superiority over exhaustion in patients." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 58, "pmid": "27718847", "title": "Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.", "citation": "Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2016.", "doi": "10.1056/NEJMoa1606774", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27718847/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27718847/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27718847", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "what_it_does_not_show": "The selection was before outcome but defines a narrower context; clinical benefit is not terminal-state reversal.", "confounders_present": [ "The selection was before outcome but defines a narrower context; clinical benefit is not terminal-state reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 59, "pmid": "28636851", "title": "First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.", "citation": "Carbone DP, Reck M, Paz-Ares L et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017.", "doi": "10.1056/NEJMoa1613493", "pmcid": "PMC6487310", "url": "https://pubmed.ncbi.nlm.nih.gov/28636851/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28636851/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID28636851", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "what_it_does_not_show": "This null pertains to its treatment, comparator and population, not absence of all exhausted cells or failure of every checkpoint regimen.", "confounders_present": [ "This null pertains to its treatment, comparator and population, not absence of all exhausted cells or failure of every checkpoint regimen." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 60, "pmid": "32437507", "title": "Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.", "citation": "Reardon DA, Brandes AA, Omuro A et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA oncology. 2020.", "doi": "10.1001/jamaoncol.2020.1024", "pmcid": "PMC7243167", "url": "https://pubmed.ncbi.nlm.nih.gov/32437507/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32437507/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32437507", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods, 2:Results, 3:Discussion. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "what_it_does_not_show": "Archival biomarker tissue, unstandardized MGMT and small subgroups limit mechanisms; subgroup trends do not rescue the null primary outcome.", "confounders_present": [ "Archival biomarker tissue, unstandardized MGMT and small subgroups limit mechanisms; subgroup trends do not rescue the null primary outcome." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 61, "pmid": "34051178", "title": "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.", "citation": "Powles T, Csőszi T, Özgüroğlu M et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2021.", "doi": "10.1016/S1470-2045(21)00152-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34051178/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34051178/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34051178", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "what_it_does_not_show": "Nominal P values or exploratory subsets cannot override the testing hierarchy; the trial does not directly measure exhaustion mediation.", "confounders_present": [ "Nominal P values or exploratory subsets cannot override the testing hierarchy; the trial does not directly measure exhaustion mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 62, "pmid": "33264544", "title": "Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.", "citation": "André T, Shiu KK, Kim TW et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine. 2020.", "doi": "10.1056/NEJMoa2017699", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33264544/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33264544/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33264544", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "what_it_does_not_show": "OS is not mature in this examined interim report and results cannot be generalized to microsatellite-stable colorectal cancer.", "confounders_present": [ "OS is not mature in this examined interim report and results cannot be generalized to microsatellite-stable colorectal cancer." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 63, "pmid": "27521269", "title": "Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.", "citation": "Schietinger A, Philip M, Krisnawan VE et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. 2016.", "doi": "10.1016/j.immuni.2016.07.011", "pmcid": "PMC5119632", "url": "https://pubmed.ncbi.nlm.nih.gov/27521269/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27521269/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Inducible AST SV40 liver-antigen platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "what_it_does_not_show": "Model antigen and restricted TCR context do not establish human checkpoint-driven initiation; this shares the liver platform with later chromatin and TOX work.", "confounders_present": [ "Model antigen and restricted TCR context do not establish human checkpoint-driven initiation; this shares the liver platform with later chromatin and TOX work." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 64, "pmid": "31207603", "title": "TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.", "citation": "Khan O, Giles JR, McDonald S et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019.", "doi": "10.1038/s41586-019-1325-x", "pmcid": "PMC6713202", "url": "https://pubmed.ncbi.nlm.nih.gov/31207603/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31207603/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Chronic-stimulation TOX lineage program", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation.", "what_it_does_not_show": "Lineage commitment mainly from experimental chronic stimulation does not alone prove that removing TOX restores human tumour control.", "confounders_present": [ "Lineage commitment mainly from experimental chronic stimulation does not alone prove that removing TOX restores human tumour control." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 65, "pmid": "30635237", "title": "Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.", "citation": "Siddiqui I, Schaeuble K, Chennupati V et al. Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019.", "doi": "10.1016/j.immuni.2018.12.021", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30635237/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30635237/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30635237", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "what_it_does_not_show": "The source of benefit is distinct from reversal of terminal exhaustion and human observations remain complementary rather than equivalent causal tests.", "confounders_present": [ "The source of benefit is distinct from reversal of terminal exhaustion and human observations remain complementary rather than equivalent causal tests." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 66, "pmid": "29443960", "title": "TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.", "citation": "Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018.", "doi": "10.1038/nature25501", "pmcid": "PMC6028240", "url": "https://pubmed.ncbi.nlm.nih.gov/29443960/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29443960/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29443960", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "what_it_does_not_show": "Human signatures are observational and combination effects do not establish TGFbeta alone as a universal human dominant bottleneck.", "confounders_present": [ "Human signatures are observational and combination effects do not establish TGFbeta alone as a universal human dominant bottleneck." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 67, "pmid": "30814732", "title": "NR4A transcription factors limit CAR T cell function in solid tumours.", "citation": "Chen J, López-Moyado IF, Seo H et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019.", "doi": "10.1038/s41586-019-0985-x", "pmcid": "PMC6546093", "url": "https://pubmed.ncbi.nlm.nih.gov/30814732/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30814732/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Engineered hCD19 CAR and NR4A platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "what_it_does_not_show": "Artificial antigen and CAR system limit transfer to endogenous human cancers; shared TOX/TOX2 CAR platform limits independence.", "confounders_present": [ "Artificial antigen and CAR system limit transfer to endogenous human cancers; shared TOX/TOX2 CAR platform limits independence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 68, "pmid": "40053604", "title": "Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate.", "citation": "Huang YJ, Ngiow SF, Baxter AE et al. Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate. Science immunology. 2025.", "doi": "10.1126/sciimmunol.ado3032", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40053604/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40053604/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related TOX program, inducible maintenance intervention", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "what_it_does_not_show": "Continuous maintenance and plasticity coexist with survival costs; the abstract does not specify the whole model scope or prove clinical terminal human tumour reversal.", "confounders_present": [ "Continuous maintenance and plasticity coexist with survival costs; the abstract does not specify the whole model scope or prove clinical terminal human tumour reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 69, "pmid": "42329236", "title": "The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.", "citation": "Ongaro M, Thouenon R, Crespo I et al. The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells. The Journal of experimental medicine. 2026.", "doi": "10.1084/jem.20252115", "pmcid": "PMC13285691", "url": "https://pubmed.ncbi.nlm.nih.gov/42329236/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42329236/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID42329236", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph19, 1:Results:paragraph21, 1:Results:paragraph24, 1:Results:paragraph25, 1:Results:paragraph26, 1:Results:paragraph27, 1:Results:paragraph30. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal experimental", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression.", "what_it_does_not_show": "Tumour-versus-virus regulation supports context specificity rather than a universal common pathway or direct human dominance.", "confounders_present": [ "Tumour-versus-virus regulation supports context specificity rather than a universal common pathway or direct human dominance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 75, "verified": 75, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Inflammation association without pathway-specific causality caps at Β.", "specific_trigger": "Reproducible human cellular states and functional patterns establish association; neither receptor expression nor an atlas alone demonstrates pathway-specific clinical causality.", "resulting_ceiling": "Β" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Checkpoint-driven, epigenetically fixed CD8+ T-cell exhaustion is the dominant mechanism by which human solid tumours evade immune control.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Immunology Γ caps ex-vivo-only or correlational human-plus-in-vitro causal claims. Cell-resolved in-vivo perturbations cross that boundary for SC2 and SC3; clinical targeted-therapy effects can attain upper levels for efficacy. These narrower successes do not lift SC4 or SC5. Cancer-rubric progression and relapse effects remain distinct from incidence/initiation or universal escape necessity.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID31207604, PMID37537361, PMID39121849, PMID28514453, PMID27521269, PMID31207603", "gamma_hard_rules_triggered": [ "Human cell states are associative for causal inference." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Reproducible human cellular states and functional patterns establish association; neither receptor expression nor an atlas alone demonstrates pathway-specific clinical causality.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID30778252, PMID33795428, PMID35978192, PMID33398183, PMID31207604, PMID36208623, PMID35623342, PMID33636129, PMID31207605, PMID38091951, PMID37537361, PMID31152140, PMID34879221, PMID34031618, PMID27501248, PMID41299179, PMID37968405, PMID41005293, PMID39322665, PMID27789795, PMID28514453, PMID27521269, PMID31207603, PMID30635237, PMID30814732, PMID40053604, PMID42329236", "gamma_hard_rules_triggered": [ "Timed and cell-resolved interventions exceed ex-vivo-only support within their specified scope." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Defined antigen, chromatin trajectories, TOX or NR4A and other lineage interventions converge on a distinct maintained program in specified experimental contexts; tumour and virus programs are not identical.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID30778252, PMID33795428, PMID33398183, PMID31207604, PMID36208623, PMID35623342, PMID33636129, PMID39121848, PMID31207605, PMID38091951, PMID39121849, PMID32937153, PMID31152140, PMID34879221, PMID34031618, PMID33007259, PMID41299179, PMID37968405, PMID41005293, PMID39322665, PMID36543958, PMID34102137, PMID39282897, PMID35403841, PMID26027431, PMID20525992, PMID29562145, PMID25891173, PMID26412456, PMID26028407, PMID36171287, PMID32497499, PMID31028147, PMID33644766, PMID37392735, PMID27828943, PMID42361199, PMID27433843, PMID27903500, PMID27718847, PMID28636851, PMID32437507, PMID34051178, PMID33264544, PMID30635237, PMID29443960, PMID30814732, PMID40053604, PMID42329236", "gamma_hard_rules_triggered": [ "Interventions support contribution, with unresolved clinical mediation and boundary conditions." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Complementary cell-resolved genetic and targeted pathway interventions change tumour control in prespecified inflamed antigen-presenting models, with human efficacy providing compatible clinical evidence. No claim that terminal exhaustion is the exclusive mediator is made.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID30778252, PMID33795428, PMID35978192, PMID31207604, PMID36208623, PMID39121848, PMID31207605, PMID38091951, PMID39121849, PMID34031618, PMID27501248, PMID33007259, PMID41299179, PMID37968405, PMID39322665, PMID27789795, PMID28514453, PMID27521269, PMID30635237, PMID40053604", "gamma_hard_rules_triggered": [ "No literal ex-vivo-only cap is imposed on the entire in-vivo corpus; the proposed terminal-reversal discriminator is missing or contradicted under ordinary blockade." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Ordinary PD1 benefit often arises from progenitor expansion, persistence or newly detected clones; direct reversal of pre-existing terminal human cells is not established. Distinct rest or cytokine interventions demonstrate partial plasticity rather than validating PD1 reversal.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID33398183, PMID35623342, PMID32937153, PMID34879221, PMID41005293, PMID36543958, PMID34102137, PMID39282897, PMID35403841, PMID26027431, PMID20525992, PMID29562145, PMID25891173, PMID26412456, PMID26028407, PMID36171287, PMID32497499, PMID31028147, PMID33644766, PMID37392735, PMID27828943, PMID42361199, PMID27433843, PMID27903500, PMID27718847, PMID28636851, PMID32437507, PMID34051178, PMID33264544, PMID29443960, PMID42329236", "gamma_hard_rules_triggered": [ "No manufactured one-model cap is imposed on this diverse corpus; comparative human dominance remains untested." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Human clinical efficacy and mechanistic mouse studies do not compare causal dominance across presentation-defective, excluded, myeloid-suppressed and inflamed solid tumours. Negative randomized trials and alternative escape mechanisms block generalization.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.", "satisfied": "no", "supporting_evidence": [ "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[15] Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[64] TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation." ], "what_would_cross_it": "Broader causal interpretation requires cell-resolved intervention with relevant tumour control, rather than greater receptor abundance." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[4] MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[15] Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[22] TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[50] PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[64] TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires context-specific causality with explicit scope restriction.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[4] MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[15] Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[22] TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[50] PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[64] TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[4] MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[15] Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[22] TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[50] PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[64] TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Η", "requirement_quoted": "Requires robust upstream causal evidence across systems and interventions.", "satisfied": "no", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[4] MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[15] Tumour-antigen exposure induces early functional and molecular dysfunction before cell division.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[22] TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[50] PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[64] TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "Wider human lineage generalization requires timed perturbation of established states with surviving clone controls, chromatin and durable function." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[11] Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[17] Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[23] Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[31] Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "[33] Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "[34] Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "[35] Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "[36] Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "[37] Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "[38] CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "[39] KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "[40] CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "[41] CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "[42] Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "[43] Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "[44] PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "[45] CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "[46] Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "[48] PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "[49] MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "[55] Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "[56] Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "[58] KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "[59] CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "[60] Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "[61] KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "[62] KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[66] Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ε", "requirement_quoted": "Requires context-specific causality with explicit scope restriction.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[11] Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[17] Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[23] Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[31] Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "[33] Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "[34] Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "[35] Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "[36] Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "[37] Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "[38] CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "[39] KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "[40] CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "[41] CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "[42] Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "[43] Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "[44] PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "[45] CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "[46] Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "[48] PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "[49] MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "[55] Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "[56] Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "[58] KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "[59] CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "[60] Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "[61] KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "[62] KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[66] Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ζ", "requirement_quoted": "Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.", "satisfied": "yes", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[11] Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[17] Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[23] Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[31] Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "[33] Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "[34] Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "[35] Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "[36] Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "[37] Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "[38] CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "[39] KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "[40] CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "[41] CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "[42] Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "[43] Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "[44] PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "[45] CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "[46] Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "[48] PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "[49] MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "[55] Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "[56] Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "[58] KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "[59] CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "[60] Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "[61] KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "[62] KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[66] Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Η", "requirement_quoted": "Requires robust upstream causal evidence across systems and interventions.", "satisfied": "no", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[10] In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential.", "[11] Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[17] Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "[18] TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[23] Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[31] Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "[33] Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "[34] Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "[35] Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "[36] Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "[37] Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "[38] CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "[39] KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "[40] CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "[41] CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "[42] Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "[43] Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "[44] PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "[45] CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "[46] Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "[48] PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "[49] MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "[55] Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "[56] Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "[58] KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "[59] CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "[60] Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "[61] KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "[62] KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[66] Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "[67] NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "Human mediator-specific control requires a prospective intervention separating exhaustion programs from priming, recruitment and other immune compartments." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.", "satisfied": "no", "supporting_evidence": [ "[1] Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness.", "[3] Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems.", "[4] MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection.", "[7] Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context.", "[8] Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells.", "[11] Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency.", "[13] During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology.", "[14] STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function.", "[16] Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes.", "[21] IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models.", "[22] TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV.", "[23] Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary.", "[25] PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death.", "[28] In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming.", "[30] FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts.", "[50] PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory.", "[51] Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs.", "[63] Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states.", "[65] Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source.", "[68] Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility." ], "what_would_cross_it": "Label established terminal tumour-reactive human clones before blockade, then demonstrate durable chromatin and functional reversal, not selective survival or replacement." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.", "satisfied": "no", "supporting_evidence": [ "[5] Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy.", "[9] Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit.", "[17] Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity.", "[19] IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary.", "[29] ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function.", "[31] Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control.", "[33] Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population.", "[34] Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens.", "[35] Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit.", "[36] Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity.", "[37] Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population.", "[38] CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group.", "[39] KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab.", "[40] CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab.", "[41] CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups.", "[42] Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models.", "[43] Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs.", "[44] PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations.", "[45] CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses.", "[46] Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations.", "[48] PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models.", "[49] MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints.", "[55] Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation.", "[56] Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling.", "[58] KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers.", "[59] CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar.", "[60] Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating.", "[61] KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory.", "[62] KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population.", "[66] Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model.", "[69] IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression." ], "what_would_cross_it": "Prespecify representative inflamed, excluded and presentation-defective human tumours, compare barrier-specific causal interventions and show exhaustion has dominant attributable effects with appropriate rescue." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "TOX-deficient tumour T cells lose receptor signatures without functional rescue and fail to persist.", "Bystander and acute-infection controls distinguish persistent tumour antigen from the same microenvironment alone.", "Progenitor ablation restricts response; terminal cells are not interchangeable with that compartment.", "Checkpoint026,143 and361 preserve negative prespecified primary outcomes.", "CAF genotype and toxin controls plus CD8 depletion test stromal intervention specificity." ], "note": "Boundaries are mapped before outcome across antigen presentation, T-cell infiltration, lineage compartment, chronic virus versus tumour, native versus CAR/artificial antigen, tumour histology and disease stage. PD-L1-high and MSI-high enrollment are valid prospective scopes; selecting responders after treatment is not. Cytotoxic CD4, Treg and myeloid mechanisms remain in the comparison." }, "falsification_patterns_met": [ { "pattern": "Phenotype signature removed without claimed functional rescue", "evidence": "Scott Tox deletion uncouples receptor expression from cytokines and killing, then loses persistence.", "downgrade_applied": false }, { "pattern": "Intervention efficacy without terminal-state reversal", "evidence": "TCF1 subset ablation, clonal appearance and persistent exhausted phenotypes separate clinical response from the nominal mediation claim.", "downgrade_applied": false }, { "pattern": "Specific intervention has context-restricted clinical efficacy", "evidence": "Negative CheckMate026 and143 and multiplicity-corrected KEYNOTE361 contrast with positive disease-specific trials.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Checkpoint marker treated as causal exhaustion", "where": "TOX marker/function uncoupling and observational state cards retain the distinction." }, { "pitfall": "Therapeutic efficacy substituted for terminal reversal", "where": "Clinical endpoints, clonal dynamics and chromatin mechanisms are separate sensitivities." }, { "pitfall": "Chronic virus substituted for human tumour proof", "where": "Viral lineage experiments are explicitly tagged; IRF8 contrasts expose mechanistic differences." }, { "pitfall": "Newly detected clone treated as proven newly recruited cell", "where": "Original Yost sampling caveat and alternative sources are retained." }, { "pitfall": "Fixed treated as absolutely irreversible", "where": "CAR rest, IL10-Fc, FcIL4, STAT5 and inducible TOX loss support intervention-dependent plasticity." }, { "pitfall": "Provider paper identity trusted without reconciliation", "where": "Consensus Pro substituted Khan for Scott; no substituted Scott details were promoted." } ], "causal_tally_audit": { "tally_claimed_by_document": 56, "tally_after_audit": 56, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines." ] }, "steelman": { "case_one_rung_higher": "Δ for pan-solid-tumour dominance would require a comparative human bottleneck perturbation, not merely positive treatment trials in selected diseases. Η for SC2 or SC3 would require broader endogenous context and human mediation convergence beyond model antigens and partly shared platforms.", "case_one_rung_lower": "Β for the scope-matched causal hypothesis would omit the extensive in-vivo perturbational and mechanistic basis. Conversely, the strongest Δ proposal based on clinical efficacy tests a weaker claim than universal fixed-exhaustion dominance.", "which_rejected": "Retain Γ for the registered broad gate and Ζ for defined experimental contribution; retain the separate Η clinical-efficacy sensitivity. The real exhaustion phenomenon and clinical benefits are not labelled refuted.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: A prospective multicancer study enrolls prespecified inflamed antigen-presenting, excluded and presentation-defective strata; randomizes matched checkpoint, lineage-reprogramming and alternative-barrier interventions; tracks pretreatment terminal and progenitor tumour-reactive clones separately with state, function and durable tumour outcomes." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered scope-matched gate SC5 yields Γ. Defined experimental lineage and tumour-control sensitivities reach Ζ; clinical checkpoint efficacy alone can reach Η in selected indications, but neither establishes terminal-state mediation or cross-solid-tumour dominance. The weakest-link bundle would be Β because of the observational existence subclaim; it is not the registered gate." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Persistent antigen, hypoxia and stromal or myeloid inputs often precede dysfunction, but specific immune-program and precursor perturbations alter control, preventing a purely noncausal or downstream-only classification at steps1–2. Pan-tumour initiation, prevention and rate limitation or universal necessity are not established at steps3–4. The program can stabilize immune escape and preserve some persistent T-cell activity, meeting step5 within mapped contexts.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Decisive work underway", "artifact": "Named recent primary perturbation studies in this corpus test mechanistic or functional boundaries; no claim of a presently recruiting trial is made.", "justification": "Named recent primary perturbation studies in this corpus test mechanistic or functional boundaries; no claim of a presently recruiting trial is made." }, "stability": { "value": "Stable", "trigger": "No named pending result is asserted to be likely to move the registered score imminently.", "justification": "No named pending result is asserted to be likely to move the registered score imminently." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "Ranking categorical verdict visible; no prior letter used as a target", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "A prospective multicancer study enrolls prespecified inflamed antigen-presenting, excluded and presentation-defective strata; randomizes matched checkpoint, lineage-reprogramming and alternative-barrier interventions; tracks pretreatment terminal and progenitor tumour-reactive clones separately with state, function and durable tumour outcomes.", "readout": "Clonal survival versus recruitment, durable chromatin and cytotoxic changes, objective tumour control and progression or survival, analyzed by baseline stratum", "critical_control": "Antigen-specific and bystander controls, receptor-signature versus killing assays, equivalent target engagement, terminal versus progenitor tracing, and matched stromal or presentation rescue", "supporting_result": "In most representative strata direct exhaustion-program reversal accounts for the largest causal control effect, traced terminal clones recover durably, and alternative barrier removal adds little with verified engagement", "falsifying_result": "Benefit depends on progenitors, new clones or another baseline barrier, or terminal signatures change without function and persistence" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Which established human terminal clones can be durably reprogrammed without depletion or replacement, and which interventions accomplish this?", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Can prospective barrier-stratified clinical comparisons estimate causal dominance rather than predict response from correlated signatures?", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "How do TOX and checkpoint functions balance survival, function and immunopathology across early and terminal states?", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "How do tumour-specific IRF8 and chronic-virus IFN programs alter the transportability of lineage results?", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "What explains target-engaged negative clinical settings and which alternative barriers must be removed before CD8-directed treatment?", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Can shared clone specificity, spatial niches and longitudinal blood or node sampling distinguish recruitment from rare pre-existing cells with known detection limits?", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-05", "reviewer": "Codex", "evidence_base_note": "69 primary reports; cutoff 2026-10-05; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Europe PMC; signed-in Consensus browser discovery and attempted indexed full-text extraction. Successful passages and failures are reconciled with original sections where available; see case reconciliation. Zero Consensus API calls.", "skill_version": "5.3", "validator_run": "exact archived v5.3 validator 2.3; see validator.txt", "validator_warnings_addressed": "Phenomenon entry was restated as the preregistered causal claim. No real phenomenon is labelled refuted; warning is explicitly justified.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Targeted checkpoint interventions against hard clinical endpoints are live upper-ladder equivalents. Multiple separate randomized melanoma, lung, renal and biomarker-selected colorectal trials justify Η for scoped clinical efficacy as a sensitivity, while null contexts remain explicit. Η, Θ and Ω for terminal reversal or pan-solid-tumour dominance require lineage-specific mediation, comparative bottleneck tests and predictive consistency; they cannot borrow the efficacy score." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Targeted checkpoint interventions against hard clinical endpoints are live upper-ladder equivalents. Multiple separate randomized melanoma, lung, renal and biomarker-selected colorectal trials justify Η for scoped clinical efficacy as a sensitivity, while null contexts remain explicit. Η, Θ and Ω for terminal reversal or pan-solid-tumour dominance require lineage-specific mediation, comparative bottleneck tests and predictive consistency; they cannot borrow the efficacy score." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Targeted checkpoint interventions against hard clinical endpoints are live upper-ladder equivalents. Multiple separate randomized melanoma, lung, renal and biomarker-selected colorectal trials justify Η for scoped clinical efficacy as a sensitivity, while null contexts remain explicit. Η, Θ and Ω for terminal reversal or pan-solid-tumour dominance require lineage-specific mediation, comparative bottleneck tests and predictive consistency; they cannot borrow the efficacy score." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "Targeted checkpoint interventions against hard clinical endpoints are live upper-ladder equivalents. Multiple separate randomized melanoma, lung, renal and biomarker-selected colorectal trials justify Η for scoped clinical efficacy as a sensitivity, while null contexts remain explicit. Η, Θ and Ω for terminal reversal or pan-solid-tumour dominance require lineage-specific mediation, comparative bottleneck tests and predictive consistency; they cannot borrow the efficacy score." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "Targeted checkpoint interventions against hard clinical endpoints are live upper-ladder equivalents. Multiple separate randomized melanoma, lung, renal and biomarker-selected colorectal trials justify Η for scoped clinical efficacy as a sensitivity, while null contexts remain explicit. Η, Θ and Ω for terminal reversal or pan-solid-tumour dominance require lineage-specific mediation, comparative bottleneck tests and predictive consistency; they cannot borrow the efficacy score." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 69, "claims_total": 75, "claims_verified": 75, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 69, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Progenitor exhausted T cells sustain tumour control and respond to checkpoint therapy; terminal cells have different responsiveness. Subset dependency in models does not establish terminal-state reversal or pan-tumour dominance; linked erratum details unexamined.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C2", "text": "Single-cell NSCLC profiling resolves heterogeneous immune states and suppressive populations. Atlas association does not rank causal bottlenecks; linked erratum details unexamined.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C3", "text": "Transient CAR signaling rest restores function and remodels exhaustion-associated chromatin in engineered-cell experimental systems. CAR rest is a different intervention from PD1 blockade and does not prove terminal human tumour T-cell reversal.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C4", "text": "MYB-dependent progenitor maintenance enables checkpoint-associated response and protection during chronic viral infection. Chronic-virus lineage dependency is a mechanism comparator rather than human solid-tumour causality.", "carries_number": false, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C5", "text": "Continuous antigen plus hypoxia promotes metabolic dysfunction; reducing hypoxic stress improves experimental immunotherapy. Metabolic and environmental effects are not isolated proof that checkpoints initiate the epigenetic program.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C6", "text": "Multiregion human lung-cancer profiling links persistent progenitor clones in lymph nodes with tumour descendants. Clonal and computational relationships are not direct in-vivo human fate labeling or universal causal mediation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C7", "text": "Original Methods and Results show tumour-specific Tox deletion removes inhibitory receptor signatures but retains impaired cytokines and killing, followed by loss of persistence; bystander and acute-infection controls separate antigen context. TOX marker loss is not functional rescue. Experiments were not randomized or blinded and had no sample-size predetermination; human samples are observational, including infiltrate-selected breast cancers.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph6, 0:METHODS:paragraph11, 0:METHODS:paragraph13, 0:METHODS:paragraph14, 0:METHODS:paragraph17, 0:METHODS:paragraph18, 0:METHODS:paragraph23, 0:METHODS:paragraph31, 0:METHODS:paragraph37, 0:METHODS:paragraph38, 3:Main text (unsectioned body paragraphs):paragraph0, 3:Main text (unsectioned body paragraphs):paragraph1, 3:Main text (unsectioned body paragraphs):paragraph2, 3:Main text (unsectioned body paragraphs):paragraph3, 3:Main text (unsectioned body paragraphs):paragraph4, 3:Main text (unsectioned body paragraphs):paragraph5, 3:Main text (unsectioned body paragraphs):paragraph6, 3:Main text (unsectioned body paragraphs):paragraph7, 3:Main text (unsectioned body paragraphs):paragraph8, 3:Main text (unsectioned body paragraphs):paragraph9, 3:Main text (unsectioned body paragraphs):paragraph10, 3:Main text (unsectioned body paragraphs):paragraph11. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C8", "text": "Tumour-draining-node memory-like cells supply checkpoint-responsive progenitors with epigenetic states distinct from exhausted tumour cells. A nodal source mechanism does not establish reversal of terminal intratumoral cells or clinical dominance.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C9", "text": "Macrophage depletion and antigen-specific interactions implicate a reciprocal macrophage-exhausted T-cell circuit. Changing macrophages affects additional functions and does not establish a single universal exhaustion bottleneck.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C10", "text": "In-vivo CRISPR and Fli1 perturbation improve effector responses and tumour or infection control while preserving precursor potential. Different disease systems and transcription-factor perturbation do not isolate ordinary PD1-mediated terminal reversal.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C11", "text": "Combined LAG3 and PD1 genetic interventions improve experimental clearance and survival with autocrine IFNgamma dependency. Dual conditional pathway effects do not prove that all human resistant tumours are limited by fixed CD8 exhaustion.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C12", "text": "Integrated chromatin and transcriptional datasets plus viral experiments resolve exhaustion-associated trajectories. Reused atlas datasets share failure modes and viral mechanisms need separate tumour validation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C13", "text": "During chronic infection TOX loss transiently increases function but removes progenitor support and persistence with immunopathology. The outcome argues against a simple uniformly harmful lineage; it is not a human tumour treatment trial.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C14", "text": "STAT5 and orthogonal cytokine signaling partially reprogram exhausted cells and improve experimental antitumour function. Targeted cytokine rewiring is not equivalent to PD1 blockade or complete durable terminal-state reversal in patients.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C15", "text": "Tumour-antigen exposure induces early functional and molecular dysfunction before cell division. Rapid onset in a defined model does not identify a checkpoint as the initiating cause across solid tumours.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C16", "text": "Human melanoma nivolumab and relatlimab immune profiling shows enhanced cytotoxicity with retained exhaustion signatures and clonal changes. Molecular response is compatible with continuing exhaustion programs; it is not a terminal-fate-mediated survival trial.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C17", "text": "Cell-resolved glucocorticoid receptor and myeloid steroidogenesis interventions improve antitumour immunity. Parallel environmental suppression and checkpoint effects need mediation separation.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C18", "text": "TOX/TOX2 perturbation in an engineered CAR setting implicates a feedback program with NR4A in hyporesponsiveness. Shared CAR platform with NR4A experiments limits independence; linked erratum details unexamined.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C19", "text": "IL10R and STAT3 support progenitor-like T cells and disease control in CLL models; human breast observations are complementary. CLL is not a solid tumour and protective IL10 effects are context dependent; no cross-solid-tumour clinical proof.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C20", "text": "Original Results profile 11 paired BCC patients and four SCC patients; bulk TCR sequencing in eight BCC patients and serial same-site biopsies address sampling. Expanded exhausted clones often are newly detected and retain exhausted phenotypes. The source of new clones was not identified and rare tumour-resident cells remain possible. Blood detection supports but does not prove recruitment; this is not terminal-state lineage perturbation in humans.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Main. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C21", "text": "IL10-Fc boosts metabolic and antitumour function of terminal exhausted cells with progenitor-independent effects in models. A distinct intervention shows some plasticity but does not imply PD1 blockade normally reverses all terminal states.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C22", "text": "TCF1-associated cells supply the proliferative burst after blockade in chronic LCMV. Chronic viral infection is a mechanism comparator rather than clinical solid-tumour efficacy or human fate proof.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C23", "text": "Tumour-draining-node targeted PDL1 intervention supports progenitor seeding and tumour control; human recurrence association is complementary. Human nodal association does not establish clinical source necessity or pan-cancer mechanism dominance.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C24", "text": "Longitudinal multiregion renal-cancer samples associate maintained expanded T-cell clones with nivolumab response. Maintenance correlations constrain a universal replacement account but do not prove causally reversed terminal cells.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C25", "text": "PD1 signaling supports high-affinity stem-like T-cell maintenance; blockade can drive differentiation and death. The protective axis is context dependent and does not negate clinical benefits or prove human cross-tumour dominance.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C26", "text": "Serial melanoma profiling identifies distinct waves associated with CTLA4 and PD1 treatment and progenitor or effector responses. Temporal molecular waves do not uniquely establish reversal of pre-existing terminal cells or mediation of survival.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C27", "text": "Human lung-cancer paired samples support revival of pre-existing and new clones rather than a single universal clonal route. Clonal sampling and state inference do not directly trace terminal human T-cell reversal.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C28", "text": "In-vivo CRISPR identifies RBPJ, IRF1, ETS1 and IKAROS-dependent transitions with intervention-induced reprogramming. Gene-specific cell rewiring is distinct from routine checkpoint treatment and may alter several lineage compartments.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C29", "text": "ATF4-associated hypoxic stress can promote terminal-like dysfunction independently of TCR signaling; pathway intervention improves experimental function. Stress pathways provide an alternative input and do not establish exhaustion dominance in patients.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C30", "text": "FcIL4 improves terminal exhausted T-cell function and checkpoint synergy in experimental tumour contexts. Functional plasticity with another cytokine treatment does not establish ordinary PD1-mediated complete lineage reversal.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C31", "text": "Conditional CD39 perturbation identifies suppressive exhausted T-cell activity under hypoxic tumour conditions and improves tumour control. A suppressor mechanism in specified models does not determine prevalence or dominance across human solid cancers.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C32", "text": "Neoadjuvant glioblastoma immune profiling shows T-cell and progenitor engagement alongside persistent myeloid barriers. Target engagement does not guarantee clinical efficacy or removal of non-T-cell resistance.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C33", "text": "Randomized CheckMate649 shows nivolumab plus chemotherapy improves OS and PFS in its primary gastric-cancer CPS-defined population. Combination efficacy does not isolate CD8 exhaustion mediation or imply identical benefits in every biomarker context.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C34", "text": "Ten-year CheckMate067 follow-up supports durable melanoma survival benefit with nivolumab-containing regimens. This is follow-up of the same randomized cohort as the initial report, not an independent replication or terminal-state fate assay.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C35", "text": "Randomized CheckMate816 reports neoadjuvant lung-cancer event-free survival and pathological response benefit. The interim OS result in this report did not cross its prespecified threshold; chemotherapy combination does not isolate terminal exhaustion reversal.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C36", "text": "Initial CheckMate067 randomization demonstrates melanoma PFS benefit from nivolumab-containing regimens with higher combination toxicity. PFS and the subsequent ten-year follow-up share one cohort; neither directly proves terminal CD8 epigenetic reversal. Linked erratum details unexamined.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C37", "text": "Randomized ipilimumab treatment improves metastatic melanoma survival in the enrolled HLA-selected population. CTLA4 acts in broader immune compartments and the trial does not identify terminal CD8 exhaustion as the dominant mediator; linked erratum details unexamined.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C38", "text": "CheckMate214 improves OS and response in the prespecified intermediate or poor-risk renal-cancer group. PFS did not meet the prespecified significance threshold and favorable-risk or mechanistic generalization is separate.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C39", "text": "KEYNOTE006 randomization demonstrates melanoma survival and PFS benefit of pembrolizumab versus ipilimumab. A comparative clinical endpoint does not identify which CD8 lineage mediated benefit.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C40", "text": "CheckMate057 improves previously treated nonsquamous NSCLC survival with nivolumab. Median PFS was not uniformly favorable and PD-L1-dependent heterogeneity does not establish cross-tumour dominance.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C41", "text": "CheckMate017 improves previously treated squamous NSCLC survival regardless of measured PD-L1 groups. Clinical efficacy is not an assay of exhaustion causality or terminal-state reversal.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C42", "text": "Original Results show LRRC15 CAF depletion, toxin and genotype controls, CD8-depletion reversal and improved checkpoint-associated tumour control in subcutaneous and orthotopic pancreatic models. Ablation changes total fibroblast abundance and immune state, so its full mechanism is not a single physical barrier; progression-to-size or ulceration survival is not all-cause human survival.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 4:LRRC15+ CAF depletion slows tumour growth, 6:LRRC15+ CAFs impede CD8+ T cell function, 7:LRRC15+ CAF ablation boosts ICB responses, 8:Discussion. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C43", "text": "Human bladder cytotoxic CD4 cells kill autologous tumour in an MHCII-dependent assay and are restrained by Tregs. Ex-vivo killing and response prediction do not establish in-vivo clinical necessity; CD8 exhaustion is not the only candidate compartment.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C44", "text": "PD1-positive Treg biology and conditional experiments supply a potential immunosuppressive consequence of blockade alongside gastric hyperprogression associations. Human observational hyperprogression is not randomized proof that checkpoint treatment causes accelerated disease.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C45", "text": "CD25-directed Treg depletion preserving IL2 signaling improves selected preclinical immune responses. Cross-system preclinical function is not established human solid-tumour efficacy or a universal CD8-exhaustion bottleneck.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C46", "text": "Conditional CXCR3 Treg manipulation releases DC1 cross-presentation and antitumour immunity with checkpoint combinations. Changing upstream priming provides another constraint and does not establish exhausted CD8 states as autonomous initiators.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C47", "text": "Pancreatic and multicancer profiling associates LRRC15 fibroblast programs with checkpoint nonresponse. Clinical correlations are not causal depletion results; this shares a fibroblast biological program with later intervention work.", "carries_number": true, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C48", "text": "PI3Kgamma targeting alters macrophage programs and improves experimental checkpoint responses across tumour models. The intervention is not fully cell-specific and preclinical benefit is not human clinical efficacy.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C49", "text": "MHC-I-deficient pancreatic models reveal TAP1-associated presentation and CD4 or Treg immune constraints; CTLA4 intervention improves control and metastatic endpoints. Experimental loss and engineered rescue do not determine frequency or dominance in unselected human pancreatic cancer.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C50", "text": "PDL1 blockade in chronic infection yields limited chromatin remodeling and transient response followed by renewed exhaustion; antigen removal does not produce ordinary memory. Chronic-virus stability is not absolute irreversibility under every intervention or proof of terminal human tumour fate.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C51", "text": "Original Results distinguish early plastic and later fixed mouse tumour chromatin states by IL15 reprogramming, with B16-OVA confirmation and matching features in human PD1-high TILs. The human marker and chromatin comparison does not directly test patient T-cell reversibility; fixed means resistant to the tested conditions, not forever irreprogrammable.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:CD8 T cell chromatin changes during infection, 2:Chromatin state dynamics of TST dysfunction, 3:Chromatin states are associated with reprogrammability, 4:Surface proteins associated with chromatin states, 5:Memory T cells enter state 2 dysfunction in tumors, 6:Chromatin accessibility in human TIL, 7:Discussion. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C52", "text": "Human tumour stem-like T cells occupy APC-rich niches and correlate with infiltration and nonprogressive disease. Spatial association does not prove that niche absence causes clinical escape or that terminal exhaustion dominates it.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC5" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C53", "text": "Serial melanoma biopsies associate pre-existing margin CD8 cells and PD1 or PDL1 proximity with pembrolizumab response, with independent predictive validation. Predictive association and proliferation are not a necessity perturbation or proof of terminal-state mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C54", "text": "Melanoma single-cell profiling identifies TCF7-associated states predicting checkpoint outcome and complementary experimental targets. Predictive human states do not establish fate reversal; linked erratum details unexamined.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C55", "text": "Paired melanoma relapse biopsies and functional tests identify JAK1, JAK2 and B2M resistance-associated defects affecting IFNgamma signaling or MHC-I presentation. Four patients do not estimate population prevalence or prove every escape event independently; acquired resistance is a distinct stage.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C56", "text": "Human melanoma and mismatch-repair-deficient colon nonresponse plus cell-line assays implicate JAK1/2 loss and absent IFNgamma signaling. Small selected samples and in-vitro mechanism do not establish universal primary resistance or ranking versus exhaustion.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C57", "text": "Allele-specific HLA loss and tumour phylogenetic patterns support immune selection and presentation escape in NSCLC. Computational evolutionary evidence does not directly restore HLA or quantify causal superiority over exhaustion in patients.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C58", "text": "KEYNOTE024 demonstrates PFS and OS benefit in prospectively selected PD-L1-high NSCLC lacking specified oncogenic drivers. The selection was before outcome but defines a narrower context; clinical benefit is not terminal-state reversal.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C59", "text": "CheckMate026 first-line NSCLC randomization does not improve PFS in its prespecified PD-L1-at-least-five-percent population; OS is similar. This null pertains to its treatment, comparator and population, not absence of all exhausted cells or failure of every checkpoint regimen.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C60", "text": "Original Methods and Results confirm powered CheckMate143 OS null in recurrent glioblastoma after 301 deaths; nivolumab PFS and response are inferior to bevacizumab, and steroid or MGMT subsets are hypothesis generating. Archival biomarker tissue, unstandardized MGMT and small subgroups limit mechanisms; subgroup trends do not rescue the null primary outcome.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods, 2:Results, 3:Discussion. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C61", "text": "KEYNOTE361 combination treatment misses both multiplicity-adjusted primary thresholds; subsequent monotherapy OS comparisons are exploratory. Nominal P values or exploratory subsets cannot override the testing hierarchy; the trial does not directly measure exhaustion mediation.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C62", "text": "KEYNOTE177 improves first-line colorectal-cancer PFS in the prospectively MSI-high or dMMR population. OS is not mature in this examined interim report and results cannot be generalized to microsatellite-stable colorectal cancer.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C63", "text": "Inducible autochthonous liver tumour and defined antigen show early antigen-driven dysfunction transitioning from reversible to less reversible states. Model antigen and restricted TCR context do not establish human checkpoint-driven initiation; this shares the liver platform with later chromatin and TOX work.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C64", "text": "TOX loss and molecular profiling show a defined feed-forward regulator of exhaustion differentiation under persistent stimulation. Lineage commitment mainly from experimental chronic stimulation does not alone prove that removing TOX restores human tumour control.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C65", "text": "Ablation of TCF1-positive PD1-positive tumour cells restricts checkpoint response and identifies stem-like subset expansion as its source. The source of benefit is distinct from reversal of terminal exhaustion and human observations remain complementary rather than equivalent causal tests.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 65 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C66", "text": "Human urothelial fibroblast TGFbeta signatures associate with exclusion and nonresponse; combined TGFbeta and PDL1 blockade releases infiltration and regression in a matching mouse model. Human signatures are observational and combination effects do not establish TGFbeta alone as a universal human dominant bottleneck.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 66 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C67", "text": "NR4A triple-knockout hCD19-reactive CAR T cells improve regression and survival in engineered-antigen mouse solid tumours with chromatin changes. Artificial antigen and CAR system limit transfer to endogenous human cancers; shared TOX/TOX2 CAR platform limits independence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 67 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C68", "text": "Induced TOX ablation after exhaustion establishment changes transcription and chromatin, causes apoptotic cell loss and permits more effector-like fate flexibility. Continuous maintenance and plasticity coexist with survival costs; the abstract does not specify the whole model scope or prove clinical terminal human tumour reversal.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 68 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "C69", "text": "IRF8 gain and loss perturbation alters TOX, effector molecules and experimental tumour control; chronic IFN-I repression differs from tumour expression. Tumour-versus-virus regulation supports context specificity rather than a universal common pathway or direct human dominance.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 69 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph19, 1:Results:paragraph21, 1:Results:paragraph24, 1:Results:paragraph25, 1:Results:paragraph26, 1:Results:paragraph27, 1:Results:paragraph30. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-05", "note": "" }, { "id": "CSC1", "text": "Reproducible human cellular states and functional patterns establish association; neither receptor expression nor an atlas alone demonstrates pathway-specific clinical causality.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 2, 6, 7, 12, 15, 16, 20, 24, 26, 27, 32, 47, 51, 52, 53, 54, 57, 63, 64 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-05", "note": "" }, { "id": "CSC2", "text": "Defined antigen, chromatin trajectories, TOX or NR4A and other lineage interventions converge on a distinct maintained program in specified experimental contexts; tumour and virus programs are not identical.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 18, 19, 21, 22, 25, 28, 29, 30, 50, 51, 52, 54, 63, 64, 65, 67, 68, 69 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-05", "note": "" }, { "id": "CSC3", "text": "Complementary cell-resolved genetic and targeted pathway interventions change tumour control in prespecified inflamed antigen-presenting models, with human efficacy providing compatible clinical evidence. No claim that terminal exhaustion is the exclusive mediator is made.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 3, 5, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18, 19, 21, 23, 25, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 53, 55, 56, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-05", "note": "" }, { "id": "CSC4", "text": "Ordinary PD1 benefit often arises from progenitor expansion, persistence or newly detected clones; direct reversal of pre-existing terminal human cells is not established. Distinct rest or cytokine interventions demonstrate partial plasticity rather than validating PD1 reversal.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 1, 3, 4, 6, 7, 8, 11, 13, 14, 16, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 50, 51, 54, 63, 65, 68 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-05", "note": "" }, { "id": "CSC5", "text": "Human clinical efficacy and mechanistic mouse studies do not compare causal dominance across presentation-defective, excluded, myeloid-suppressed and inflamed solid tumours. Negative randomized trials and alternative escape mechanisms block generalization.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 2, 5, 9, 17, 19, 29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 55, 56, 57, 58, 59, 60, 61, 62, 66, 69 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-05", "note": "" }, { "id": "CH", "text": "Exhaustion programs constrain immunity in defined tumour contexts, but terminal-state reversal and dominance across human solid tumours are not established.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 7, 65, 20, 60, 66, 69 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-05", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Miller BC, Sen DR, Al Abosy R et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature immunology. 2019.", "tier": "A", "kind": "primary", "pmid": "30778252", "doi": "10.1038/s41590-019-0312-6", "url": "https://pubmed.ncbi.nlm.nih.gov/30778252/", "status_flags": [ "ErratumIn: PMID31582823" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30778252", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2", "CSC3", "CSC4" ] }, { "n": 2, "citation": "Guo X, Zhang Y, Zheng L et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nature medicine. 2018.", "tier": "A", "kind": "primary", "pmid": "29942094", "doi": "10.1038/s41591-018-0045-3", "url": "https://pubmed.ncbi.nlm.nih.gov/29942094/", "status_flags": [ "ErratumIn: PMID30093729" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29942094", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC5" ] }, { "n": 3, "citation": "Weber EW, Parker KR, Sotillo E et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science (New York, N.Y.). 2021.", "tier": "A", "kind": "primary", "pmid": "33795428", "doi": "10.1126/science.aba1786", "url": "https://pubmed.ncbi.nlm.nih.gov/33795428/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33795428", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2", "CSC3", "CSC4" ] }, { "n": 4, "citation": "Tsui C, Kretschmer L, Rapelius S et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022.", "tier": "A", "kind": "primary", "pmid": "35978192", "doi": "10.1038/s41586-022-05105-1", "url": "https://pubmed.ncbi.nlm.nih.gov/35978192/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35978192", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2", "CSC4" ] }, { "n": 5, "citation": "Scharping NE, Rivadeneira DB, Menk AV et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nature immunology. 2021.", "tier": "A", "kind": "primary", "pmid": "33398183", "doi": "10.1038/s41590-020-00834-9", "url": "https://pubmed.ncbi.nlm.nih.gov/33398183/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33398183", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC3", "CSC5" ] }, { "n": 6, "citation": "Pai JA, Hellmann MD, Sauter JL et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer cell. 2023.", "tier": "A", "kind": "primary", "pmid": "37001526", "doi": "10.1016/j.ccell.2023.03.009", "url": "https://pubmed.ncbi.nlm.nih.gov/37001526/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37001526", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1", "CSC2", "CSC4" ] }, { "n": 7, "citation": "Scott AC, Dündar F, Zumbo P et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31207604", "doi": "10.1038/s41586-019-1324-y", "url": "https://pubmed.ncbi.nlm.nih.gov/31207604/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "AST liver-antigen platform; TOX perturbation and human samples", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph6, 0:METHODS:paragraph11, 0:METHODS:paragraph13, 0:METHODS:paragraph14, 0:METHODS:paragraph17, 0:METHODS:paragraph18, 0:METHODS:paragraph23, 0:METHODS:paragraph31, 0:METHODS:paragraph37, 0:METHODS:paragraph38, 3:Main text (unsectioned body paragraphs):paragraph0, 3:Main text (unsectioned body paragraphs):paragraph1, 3:Main text (unsectioned body paragraphs):paragraph2, 3:Main text (unsectioned body paragraphs):paragraph3, 3:Main text (unsectioned body paragraphs):paragraph4, 3:Main text (unsectioned body paragraphs):paragraph5, 3:Main text (unsectioned body paragraphs):paragraph6, 3:Main text (unsectioned body paragraphs):paragraph7, 3:Main text (unsectioned body paragraphs):paragraph8, 3:Main text (unsectioned body paragraphs):paragraph9, 3:Main text (unsectioned body paragraphs):paragraph10, 3:Main text (unsectioned body paragraphs):paragraph11. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 8, "citation": "Huang Q, Wu X, Wang Z et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022.", "tier": "A", "kind": "primary", "pmid": "36208623", "doi": "10.1016/j.cell.2022.09.020", "url": "https://pubmed.ncbi.nlm.nih.gov/36208623/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID36208623", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC2", "CSC3", "CSC4" ] }, { "n": 9, "citation": "Kersten K, Hu KH, Combes AJ et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer cell. 2022.", "tier": "A", "kind": "primary", "pmid": "35623342", "doi": "10.1016/j.ccell.2022.05.004", "url": "https://pubmed.ncbi.nlm.nih.gov/35623342/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35623342", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC3", "CSC5" ] }, { "n": 10, "citation": "Chen Z, Arai E, Khan O et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021.", "tier": "A", "kind": "primary", "pmid": "33636129", "doi": "10.1016/j.cell.2021.02.019", "url": "https://pubmed.ncbi.nlm.nih.gov/33636129/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33636129", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CSC3" ] }, { "n": 11, "citation": "Andrews LP, Butler SC, Cui J et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024.", "tier": "A", "kind": "primary", "pmid": "39121848", "doi": "10.1016/j.cell.2024.07.016", "url": "https://pubmed.ncbi.nlm.nih.gov/39121848/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39121848", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC3", "CSC4" ] }, { "n": 12, "citation": "Pritykin Y, van der Veeken J, Pine AR et al. A unified atlas of CD8 T cell dysfunctional states in cancer and infection. Molecular cell. 2021.", "tier": "A", "kind": "primary", "pmid": "33891860", "doi": "10.1016/j.molcel.2021.03.045", "url": "https://pubmed.ncbi.nlm.nih.gov/33891860/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Integrated public exhaustion datasets plus new viral experiments", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC2" ] }, { "n": 13, "citation": "Alfei F, Kanev K, Hofmann M et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31207605", "doi": "10.1038/s41586-019-1326-9", "url": "https://pubmed.ncbi.nlm.nih.gov/31207605/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31207605", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC2", "CSC3", "CSC4" ] }, { "n": 14, "citation": "Beltra JC, Abdel-Hakeem MS, Manne S et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. Immunity. 2023.", "tier": "A", "kind": "primary", "pmid": "38091951", "doi": "10.1016/j.immuni.2023.11.005", "url": "https://pubmed.ncbi.nlm.nih.gov/38091951/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID38091951", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC3", "CSC4" ] }, { "n": 15, "citation": "Rudloff MW, Zumbo P, Favret NR et al. Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division. Nature immunology. 2023.", "tier": "A", "kind": "primary", "pmid": "37537361", "doi": "10.1038/s41590-023-01578-y", "url": "https://pubmed.ncbi.nlm.nih.gov/37537361/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37537361", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC2" ] }, { "n": 16, "citation": "Cillo AR, Cardello C, Shan F et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024.", "tier": "A", "kind": "primary", "pmid": "39121849", "doi": "10.1016/j.cell.2024.06.036", "url": "https://pubmed.ncbi.nlm.nih.gov/39121849/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39121849", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC1", "CSC3", "CSC4" ] }, { "n": 17, "citation": "Acharya N, Madi A, Zhang H et al. Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity. 2020.", "tier": "A", "kind": "primary", "pmid": "32937153", "doi": "10.1016/j.immuni.2020.08.005", "url": "https://pubmed.ncbi.nlm.nih.gov/32937153/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32937153", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC3", "CSC5" ] }, { "n": 18, "citation": "Seo H, Chen J, González-Avalos E et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "tier": "A", "kind": "primary", "pmid": "31152140", "doi": "10.1073/pnas.1905675116", "url": "https://pubmed.ncbi.nlm.nih.gov/31152140/", "status_flags": [ "ErratumIn: PMID31527257" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related hCD19 CAR TOX/TOX2 platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC2", "CSC3" ] }, { "n": 19, "citation": "Hanna BS, Llaó-Cid L, Iskar M et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity. 2021.", "tier": "A", "kind": "primary", "pmid": "34879221", "doi": "10.1016/j.immuni.2021.11.004", "url": "https://pubmed.ncbi.nlm.nih.gov/34879221/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34879221", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC2", "CSC3", "CSC5" ] }, { "n": 20, "citation": "Yost KE, Satpathy AT, Wells DK et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature medicine. 2019.", "tier": "A", "kind": "primary", "pmid": "31359002", "doi": "10.1038/s41591-019-0522-3", "url": "https://pubmed.ncbi.nlm.nih.gov/31359002/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31359002", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Main. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1", "CSC4", "CH" ] }, { "n": 21, "citation": "Guo Y, Xie YQ, Gao M et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nature immunology. 2021.", "tier": "A", "kind": "primary", "pmid": "34031618", "doi": "10.1038/s41590-021-00940-2", "url": "https://pubmed.ncbi.nlm.nih.gov/34031618/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34031618", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC3", "CSC4" ] }, { "n": 22, "citation": "Im SJ, Hashimoto M, Gerner MY et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016.", "tier": "A", "kind": "primary", "pmid": "27501248", "doi": "10.1038/nature19330", "url": "https://pubmed.ncbi.nlm.nih.gov/27501248/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27501248", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC2", "CSC4" ] }, { "n": 23, "citation": "Dammeijer F, van Gulijk M, Mulder EE et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer cell. 2020.", "tier": "A", "kind": "primary", "pmid": "33007259", "doi": "10.1016/j.ccell.2020.09.001", "url": "https://pubmed.ncbi.nlm.nih.gov/33007259/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33007259", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC3", "CSC4" ] }, { "n": 24, "citation": "Au L, Hatipoglu E, Robert de Massy M et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer cell. 2021.", "tier": "A", "kind": "primary", "pmid": "34715028", "doi": "10.1016/j.ccell.2021.10.001", "url": "https://pubmed.ncbi.nlm.nih.gov/34715028/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34715028", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1", "CSC4" ] }, { "n": 25, "citation": "Hor JL, Schrom EC, Wong-Rolle A et al. Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells. Nature. 2026.", "tier": "A", "kind": "primary", "pmid": "41299179", "doi": "10.1038/s41586-025-09440-x", "url": "https://pubmed.ncbi.nlm.nih.gov/41299179/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID41299179", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC2", "CSC3", "CSC4" ] }, { "n": 26, "citation": "Wang K, Coutifaris P, Brocks D et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer cell. 2024.", "tier": "A", "kind": "primary", "pmid": "39214097", "doi": "10.1016/j.ccell.2024.08.007", "url": "https://pubmed.ncbi.nlm.nih.gov/39214097/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39214097", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1", "CSC4" ] }, { "n": 27, "citation": "Liu B, Hu X, Feng K et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature cancer. 2022.", "tier": "A", "kind": "primary", "pmid": "35121991", "doi": "10.1038/s43018-021-00292-8", "url": "https://pubmed.ncbi.nlm.nih.gov/35121991/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35121991", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC1", "CSC4" ] }, { "n": 28, "citation": "Zhou P, Shi H, Huang H et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature. 2023.", "tier": "A", "kind": "primary", "pmid": "37968405", "doi": "10.1038/s41586-023-06733-x", "url": "https://pubmed.ncbi.nlm.nih.gov/37968405/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37968405", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC2", "CSC3", "CSC4" ] }, { "n": 29, "citation": "Alicea Pauneto CDM, Riesenberg BP, Gandy EJ et al. Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 2025.", "tier": "A", "kind": "primary", "pmid": "41005293", "doi": "10.1016/j.immuni.2025.09.003", "url": "https://pubmed.ncbi.nlm.nih.gov/41005293/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID41005293", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC2", "CSC3", "CSC5" ] }, { "n": 30, "citation": "Feng B, Bai Z, Zhou X et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024.", "tier": "A", "kind": "primary", "pmid": "39322665", "doi": "10.1038/s41586-024-07962-4", "url": "https://pubmed.ncbi.nlm.nih.gov/39322665/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID39322665", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC2", "CSC3", "CSC4" ] }, { "n": 31, "citation": "Vignali PDA, DePeaux K, Watson MJ et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nature immunology. 2023.", "tier": "A", "kind": "primary", "pmid": "36543958", "doi": "10.1038/s41590-022-01379-9", "url": "https://pubmed.ncbi.nlm.nih.gov/36543958/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID36543958", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC3", "CSC5" ] }, { "n": 32, "citation": "Lee AH, Sun L, Mochizuki AY et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature communications. 2021.", "tier": "A", "kind": "primary", "pmid": "34836966", "doi": "10.1038/s41467-021-26940-2", "url": "https://pubmed.ncbi.nlm.nih.gov/34836966/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34836966", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC3", "CSC5" ] }, { "n": 33, "citation": "Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England). 2021.", "tier": "A", "kind": "rct", "pmid": "34102137", "doi": "10.1016/S0140-6736(21)00797-2", "url": "https://pubmed.ncbi.nlm.nih.gov/34102137/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34102137", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC3", "CSC5" ] }, { "n": 34, "citation": "Wolchok JD, Chiarion-Sileni V, Rutkowski P et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39282897", "doi": "10.1056/NEJMoa2407417", "url": "https://pubmed.ncbi.nlm.nih.gov/39282897/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "CheckMate067 NCT01844505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC3", "CSC5" ] }, { "n": 35, "citation": "Forde PM, Spicer J, Lu S et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New England journal of medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "35403841", "doi": "10.1056/NEJMoa2202170", "url": "https://pubmed.ncbi.nlm.nih.gov/35403841/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID35403841", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC3", "CSC5" ] }, { "n": 36, "citation": "Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "26027431", "doi": "10.1056/NEJMoa1504030", "url": "https://pubmed.ncbi.nlm.nih.gov/26027431/", "status_flags": [ "ErratumIn: PMID31442371" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "CheckMate067 NCT01844505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC3", "CSC5" ] }, { "n": 37, "citation": "Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010.", "tier": "A", "kind": "rct", "pmid": "20525992", "doi": "10.1056/NEJMoa1003466", "url": "https://pubmed.ncbi.nlm.nih.gov/20525992/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID20525992", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC3", "CSC5" ] }, { "n": 38, "citation": "Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018.", "tier": "A", "kind": "rct", "pmid": "29562145", "doi": "10.1056/NEJMoa1712126", "url": "https://pubmed.ncbi.nlm.nih.gov/29562145/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29562145", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC3", "CSC5" ] }, { "n": 39, "citation": "Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "25891173", "doi": "10.1056/NEJMoa1503093", "url": "https://pubmed.ncbi.nlm.nih.gov/25891173/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID25891173", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC3", "CSC5" ] }, { "n": 40, "citation": "Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "26412456", "doi": "10.1056/NEJMoa1507643", "url": "https://pubmed.ncbi.nlm.nih.gov/26412456/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID26412456", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC3", "CSC5" ] }, { "n": 41, "citation": "Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "26028407", "doi": "10.1056/NEJMoa1504627", "url": "https://pubmed.ncbi.nlm.nih.gov/26028407/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID26028407", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC3", "CSC5" ] }, { "n": 42, "citation": "Krishnamurty AT, Shyer JA, Thai M et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022.", "tier": "A", "kind": "primary", "pmid": "36171287", "doi": "10.1038/s41586-022-05272-1", "url": "https://pubmed.ncbi.nlm.nih.gov/36171287/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related LRRC15 fibroblast lineage, distinct experimental depletion", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 4:LRRC15+ CAF depletion slows tumour growth, 6:LRRC15+ CAFs impede CD8+ T cell function, 7:LRRC15+ CAF ablation boosts ICB responses, 8:Discussion. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC3", "CSC5" ] }, { "n": 43, "citation": "Oh DY, Kwek SS, Raju SS et al. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020.", "tier": "A", "kind": "primary", "pmid": "32497499", "doi": "10.1016/j.cell.2020.05.017", "url": "https://pubmed.ncbi.nlm.nih.gov/32497499/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32497499", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC3", "CSC5" ] }, { "n": 44, "citation": "Kamada T, Togashi Y, Tay C et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "tier": "A", "kind": "primary", "pmid": "31028147", "doi": "10.1073/pnas.1822001116", "url": "https://pubmed.ncbi.nlm.nih.gov/31028147/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31028147", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC3", "CSC5" ] }, { "n": 45, "citation": "Solomon I, Amann M, Goubier A et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nature cancer. 2020.", "tier": "A", "kind": "primary", "pmid": "33644766", "doi": "10.1038/s43018-020-00133-0", "url": "https://pubmed.ncbi.nlm.nih.gov/33644766/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33644766", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC3", "CSC5" ] }, { "n": 46, "citation": "Moreno Ayala MA, Campbell TF, Zhang C et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. Immunity. 2023.", "tier": "A", "kind": "primary", "pmid": "37392735", "doi": "10.1016/j.immuni.2023.06.003", "url": "https://pubmed.ncbi.nlm.nih.gov/37392735/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID37392735", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC3", "CSC5" ] }, { "n": 47, "citation": "Dominguez CX, Müller S, Keerthivasan S et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer discovery. 2020.", "tier": "A", "kind": "primary", "pmid": "31699795", "doi": "10.1158/2159-8290.CD-19-0644", "url": "https://pubmed.ncbi.nlm.nih.gov/31699795/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Human LRRC15 fibroblast program", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC1", "CSC5" ] }, { "n": 48, "citation": "De Henau O, Rausch M, Winkler D et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016.", "tier": "A", "kind": "primary", "pmid": "27828943", "doi": "10.1038/nature20554", "url": "https://pubmed.ncbi.nlm.nih.gov/27828943/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27828943", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC3", "CSC5" ] }, { "n": 49, "citation": "Schmiechen ZC, Cruz-Hinojoza E, Hilk AL et al. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology. 2026.", "tier": "A", "kind": "primary", "pmid": "42361199", "doi": "10.1126/sciimmunol.adz4302", "url": "https://pubmed.ncbi.nlm.nih.gov/42361199/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID42361199", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC3", "CSC5" ] }, { "n": 50, "citation": "Pauken KE, Sammons MA, Odorizzi PM et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science (New York, N.Y.). 2016.", "tier": "A", "kind": "primary", "pmid": "27789795", "doi": "10.1126/science.aaf2807", "url": "https://pubmed.ncbi.nlm.nih.gov/27789795/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27789795", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC4" ] }, { "n": 51, "citation": "Philip M, Fairchild L, Sun L et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017.", "tier": "A", "kind": "primary", "pmid": "28514453", "doi": "10.1038/nature22367", "url": "https://pubmed.ncbi.nlm.nih.gov/28514453/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "AST liver-antigen platform plus B16-OVA and human chromatin", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:CD8 T cell chromatin changes during infection, 2:Chromatin state dynamics of TST dysfunction, 3:Chromatin states are associated with reprogrammability, 4:Surface proteins associated with chromatin states, 5:Memory T cells enter state 2 dysfunction in tumors, 6:Chromatin accessibility in human TIL, 7:Discussion. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC1", "CSC2", "CSC4" ] }, { "n": 52, "citation": "Jansen CS, Prokhnevska N, Master VA et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31827286", "doi": "10.1038/s41586-019-1836-5", "url": "https://pubmed.ncbi.nlm.nih.gov/31827286/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID31827286", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC1", "CSC2", "CSC5" ] }, { "n": 53, "citation": "Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014.", "tier": "A", "kind": "primary", "pmid": "25428505", "doi": "10.1038/nature13954", "url": "https://pubmed.ncbi.nlm.nih.gov/25428505/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID25428505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC1", "CSC3" ] }, { "n": 54, "citation": "Sade-Feldman M, Yizhak K, Bjorgaard SL et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018.", "tier": "A", "kind": "primary", "pmid": "30388456", "doi": "10.1016/j.cell.2018.10.038", "url": "https://pubmed.ncbi.nlm.nih.gov/30388456/", "status_flags": [ "ErratumIn: PMID30633907" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30388456", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC1", "CSC2", "CSC4" ] }, { "n": 55, "citation": "Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England journal of medicine. 2016.", "tier": "A", "kind": "primary", "pmid": "27433843", "doi": "10.1056/NEJMoa1604958", "url": "https://pubmed.ncbi.nlm.nih.gov/27433843/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27433843", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC3", "CSC5" ] }, { "n": 56, "citation": "Shin DS, Zaretsky JM, Escuin-Ordinas H et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer discovery. 2017.", "tier": "A", "kind": "primary", "pmid": "27903500", "doi": "10.1158/2159-8290.CD-16-1223", "url": "https://pubmed.ncbi.nlm.nih.gov/27903500/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27903500", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC3", "CSC5" ] }, { "n": 57, "citation": "McGranahan N, Rosenthal R, Hiley CT et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017.", "tier": "A", "kind": "primary", "pmid": "29107330", "doi": "10.1016/j.cell.2017.10.001", "url": "https://pubmed.ncbi.nlm.nih.gov/29107330/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29107330", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC1", "CSC5" ] }, { "n": 58, "citation": "Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2016.", "tier": "A", "kind": "rct", "pmid": "27718847", "doi": "10.1056/NEJMoa1606774", "url": "https://pubmed.ncbi.nlm.nih.gov/27718847/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID27718847", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC3", "CSC5" ] }, { "n": 59, "citation": "Carbone DP, Reck M, Paz-Ares L et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017.", "tier": "A", "kind": "primary", "pmid": "28636851", "doi": "10.1056/NEJMoa1613493", "url": "https://pubmed.ncbi.nlm.nih.gov/28636851/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID28636851", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC3", "CSC5" ] }, { "n": 60, "citation": "Reardon DA, Brandes AA, Omuro A et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA oncology. 2020.", "tier": "A", "kind": "rct", "pmid": "32437507", "doi": "10.1001/jamaoncol.2020.1024", "url": "https://pubmed.ncbi.nlm.nih.gov/32437507/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID32437507", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods, 2:Results, 3:Discussion. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC3", "CSC5", "CH" ] }, { "n": 61, "citation": "Powles T, Csőszi T, Özgüroğlu M et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2021.", "tier": "A", "kind": "rct", "pmid": "34051178", "doi": "10.1016/S1470-2045(21)00152-2", "url": "https://pubmed.ncbi.nlm.nih.gov/34051178/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID34051178", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC3", "CSC5" ] }, { "n": 62, "citation": "André T, Shiu KK, Kim TW et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine. 2020.", "tier": "A", "kind": "rct", "pmid": "33264544", "doi": "10.1056/NEJMoa2017699", "url": "https://pubmed.ncbi.nlm.nih.gov/33264544/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID33264544", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC3", "CSC5" ] }, { "n": 63, "citation": "Schietinger A, Philip M, Krisnawan VE et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. 2016.", "tier": "A", "kind": "primary", "pmid": "27521269", "doi": "10.1016/j.immuni.2016.07.011", "url": "https://pubmed.ncbi.nlm.nih.gov/27521269/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Inducible AST SV40 liver-antigen platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC1", "CSC2", "CSC4" ] }, { "n": 64, "citation": "Khan O, Giles JR, McDonald S et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31207603", "doi": "10.1038/s41586-019-1325-x", "url": "https://pubmed.ncbi.nlm.nih.gov/31207603/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Chronic-stimulation TOX lineage program", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C64", "CSC1", "CSC2" ] }, { "n": 65, "citation": "Siddiqui I, Schaeuble K, Chennupati V et al. Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019.", "tier": "A", "kind": "primary", "pmid": "30635237", "doi": "10.1016/j.immuni.2018.12.021", "url": "https://pubmed.ncbi.nlm.nih.gov/30635237/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID30635237", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C65", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 66, "citation": "Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018.", "tier": "A", "kind": "primary", "pmid": "29443960", "doi": "10.1038/nature25501", "url": "https://pubmed.ncbi.nlm.nih.gov/29443960/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID29443960", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C66", "CSC3", "CSC5", "CH" ] }, { "n": 67, "citation": "Chen J, López-Moyado IF, Seo H et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "30814732", "doi": "10.1038/s41586-019-0985-x", "url": "https://pubmed.ncbi.nlm.nih.gov/30814732/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Engineered hCD19 CAR and NR4A platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C67", "CSC2", "CSC3" ] }, { "n": 68, "citation": "Huang YJ, Ngiow SF, Baxter AE et al. Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate. Science immunology. 2025.", "tier": "A", "kind": "primary", "pmid": "40053604", "doi": "10.1126/sciimmunol.ado3032", "url": "https://pubmed.ncbi.nlm.nih.gov/40053604/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "Related TOX program, inducible maintenance intervention", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C68", "CSC2", "CSC3", "CSC4" ] }, { "n": 69, "citation": "Ongaro M, Thouenon R, Crespo I et al. The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells. The Journal of experimental medicine. 2026.", "tier": "A", "kind": "primary", "pmid": "42329236", "doi": "10.1084/jem.20252115", "url": "https://pubmed.ncbi.nlm.nih.gov/42329236/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-05", "status_checked_on": "2026-10-05", "study_id": "PMID42329236", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph19, 1:Results:paragraph21, 1:Results:paragraph24, 1:Results:paragraph25, 1:Results:paragraph26, 1:Results:paragraph27, 1:Results:paragraph30. No complete-paper or supplement audit claimed.", "carries_claims": [ "C69", "CSC2", "CSC3", "CSC5", "CH" ] } ], "independence_basis": { "required": true, "lines": [ { "label": "Chromatin dynamics and antigen controls", "sources": [ 63, 51, 7 ], "excludes_error": "Distinguish antigen-specific differentiation from solely bulk infiltration, while sharing a liver platform." }, { "label": "Cell-resolved program perturbations", "sources": [ 67, 28, 69 ], "excludes_error": "Reduce marker-only and purely downstream explanations; CAR/artificial-antigen boundaries persist." }, { "label": "Precursor depletion and nodal support", "sources": [ 65, 8, 23 ], "excludes_error": "Test source dependency distinct from terminal receptor abundance." }, { "label": "Independent randomized clinical settings", "sources": [ 39, 41, 38, 58, 60 ], "excludes_error": "Exclude a solely observational efficacy account and expose clinical heterogeneity; they do not directly trace exhaustion mediation." }, { "label": "Alternative barrier interventions", "sources": [ 42, 66, 46, 9 ], "excludes_error": "Challenge a sole checkpoint bottleneck using different stromal, priming and myeloid instruments." } ], "shared_failure_mode_checked": true, "note": "Different instruments exclude different errors for constrained contribution. Chronic infection is a comparator, not independent human-tumour replication. CheckMate067 early and late reports are one cohort. AST, CAR and TOX follow-ups share biological platforms; atlas reuse, shared authors and common antigens limit independence. Human state prediction, clonal tracking and randomized clinical efficacy measure different questions." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered scope-matched gate SC5 yields Γ. Defined experimental lineage and tumour-control sensitivities reach Ζ; clinical checkpoint efficacy alone can reach Η in selected indications, but neither establishes terminal-state mediation or cross-solid-tumour dominance. The weakest-link bundle would be Β because of the observational existence subclaim; it is not the registered gate." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered scope-matched gate SC5 yields Γ. Defined experimental lineage and tumour-control sensitivities reach Ζ; clinical checkpoint efficacy alone can reach Η in selected indications, but neither establishes terminal-state mediation or cross-solid-tumour dominance. The weakest-link bundle would be Β because of the observational existence subclaim; it is not the registered gate." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\hsef_v53_popularity_ranks_11_15_2026-10-05\\checkpoint-exhaustion-tumor-evasion\\consensus\\browser-proof.png", "sha256": "6e19a068d3666b6f3c6342f887eb378b1e398786d4597593f0ad5be379e363e3" }, { "path": "deliverables\\hsef_v53_popularity_ranks_11_15_2026-10-05\\checkpoint-exhaustion-tumor-evasion\\consensus\\deep-dom.txt", "sha256": "b8c8f81e306992a23d0d6a9194c142238572003f135621b4b4caba16c9a0c046" }, { "path": "deliverables\\hsef_v53_popularity_ranks_11_15_2026-10-05\\checkpoint-exhaustion-tumor-evasion\\consensus\\deep-response.txt", "sha256": "9c09fe1dad85eea7f70478f5697f0cf40bf414e990786cb418e22dea76ce9c0b" }, { "path": "deliverables\\hsef_v53_popularity_ranks_11_15_2026-10-05\\checkpoint-exhaustion-tumor-evasion\\consensus\\pro-dom.txt", "sha256": "deda34080d804a874bf182d0bc18141afc30804e1011babdd080f74c5b890c0a" }, { "path": "deliverables\\hsef_v53_popularity_ranks_11_15_2026-10-05\\checkpoint-exhaustion-tumor-evasion\\consensus\\pro-response.txt", "sha256": "2f0747a255917bca2ede727f507a7bec41e5b054949ceabf78988c66409efc54" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record." } }